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Dissecting The Functions Of Atr In Replication Fork Stability
Abstract
Genome maintenance is required for cellular viability, and failure to preserve genomic integrity is
associated with an increased risk of diseases, such as cancer. To ensure genomic stability, cells have
checkpoints that control cell cycle progression in the event of DNA damage or incomplete DNA
replication. The DNA replication checkpoint is regulated by the ATR-CHK1 pathway that stabilizes stalled
replication forks and prevents their collapse into DNA double-strand breaks (DSBs). Two distinct models
have been proposed to explain how ATR stabilizes stalled forks: 1) through local modulation of fork
remodelers, such as SMARCAL1 inhibition, and 2) through inhibition of CDK-dependent pathways, such as
inhibition of the AURKA-PLK1 pathway, which prevent cell cycle progression. However, it remains unclear
which stabilization function is essential for fork stability and whether specific sites in the genome depend
on one function over the other.
In an effort to test if an essential part of fork stabilization is mediated through inhibiting CDK-dependent
pathways, such as inhibiting premature activation of the AURKA-PLK1 pathway, we established a system
to hyper-activate the AURKA-PLK1 pathway to determine if it is sufficient to cause fork collapse. We found
that fork collapse was not achievable solely through Aurora A overexpression nor with overexpression of
its co-activators, TPX2 and BORA, but rather that CDK1 activation was also required. To test if
CDK1-activation is sufficient to promote fork collapse, we inhibited WEE1, which short-circuits the cell
cycle checkpoint function of ATR without inhibiting its fork-proximal activity. Using flow cytometry based
fork collapse assays and genome-wide detection of RPA accumulation using RPA ChIP-Seq, we show that
WEE1 and ATR inhibition cause similar levels of fork collapse at overlapping genomic locations in a
CDK1-depdendent manner under conditions of partial replication inhibition (low dose aphidicolin).
Notably, treatment with WEE1 inhibitor (WEE1i) alone was also sufficient to cause replication fork
collapse, and did so more rapidly and to a higher degree than treatment with ATR inhibitor (ATRi) alone.
Interestingly, clear differences in site specificity were observed when WEE1i was combined with ATRi,
suggesting that particular sites in the genome may be slightly more dependent on the local functions of
ATR than others. Thus, cell cycle checkpoint abrogation by WEE1i is sufficient to cause replication fork
collapse in a manner similar to ATRi; however, site-specific roles for ATR remain. Together our findings
indicate that the cell cycle checkpoint of ATR is key in stabilizing replication forks at a majority of sites in
the genome. These findings could be leveraged to develop cancer treatments that exploit combinations of
oncogenic genomic breakage signatures with that of WEE1 or ATR inhibitors.
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ABSTRACT
DISSECTING THE FUNCTIONS OF ATR IN REPLICATION FORK STABILITY
Theonie Anastassiadis
Eric J. Brown

Genome maintenance is required for cellular viability, and failure to preserve
genomic integrity is associated with an increased risk of diseases, such as cancer. To
ensure genomic stability, cells have checkpoints that control cell cycle progression in the
event of DNA damage or incomplete DNA replication. The DNA replication checkpoint is
regulated by the ATR-CHK1 pathway that stabilizes stalled replication forks and
prevents their collapse into DNA double-strand breaks (DSBs). Two distinct models have
been proposed to explain how ATR stabilizes stalled forks: 1) through local modulation
of fork remodelers, such as SMARCAL1 inhibition, and 2) through inhibition of CDKdependent pathways, such as inhibition of the AURKA-PLK1 pathway, which prevent cell
cycle progression. However, it remains unclear which stabilization function is essential
for fork stability and whether specific sites in the genome depend on one function over
the other.
In an effort to test if an essential part of fork stabilization is mediated through
inhibiting CDK-dependent pathways, such as inhibiting premature activation of the
AURKA-PLK1 pathway, we established a system to hyper-activate the AURKA-PLK1
pathway to determine if it is sufficient to cause fork collapse. We found that fork collapse
was not achievable solely through Aurora A overexpression nor with overexpression of
its co-activators, TPX2 and BORA, but rather that CDK1 activation was also required. To
test if CDK1-activation is sufficient to promote fork collapse, we inhibited WEE1, which
iv

short-circuits the cell cycle checkpoint function of ATR without inhibiting its fork-proximal
activity. Using flow cytometry based fork collapse assays and genome-wide detection of
RPA accumulation using RPA ChIP-Seq, we show that WEE1 and ATR inhibition cause
similar levels of fork collapse at overlapping genomic locations in a CDK1-depdendent
manner under conditions of partial replication inhibition (low dose aphidicolin). Notably,
treatment with WEE1 inhibitor (WEE1i) alone was also sufficient to cause replication fork
collapse, and did so more rapidly and to a higher degree than treatment with ATR
inhibitor (ATRi) alone. Interestingly, clear differences in site specificity were observed
when WEE1i was combined with ATRi, suggesting that particular sites in the genome
may be slightly more dependent on the local functions of ATR than others. Thus, cell
cycle checkpoint abrogation by WEE1i is sufficient to cause replication fork collapse in a
manner similar to ATRi; however, site-specific roles for ATR remain. Together our
findings indicate that the cell cycle checkpoint of ATR is key in stabilizing replication
forks at a majority of sites in the genome. These findings could be leveraged to develop
cancer treatments that exploit combinations of oncogenic genomic breakage signatures
with that of WEE1 or ATR inhibitors.
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CHAPTER 1: Introduction: The role of DNA replication checkpoints in replication
fork dynamics

Theonie Anastassiadis

Department of Cancer Biology, University of Pennsylvania, Philadelphia, PA,
19104, USA
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Introduction
The survival of an organism depends on its ability to faithfully and efficiently
transmit genetic material from mother to daughter cell. During each cell cycle, human
cells must accurately replicate over three billion base pairs of DNA in a short period of
time and protect the genome from spontaneous or induced DNA damage that could
result in alterations or loss of genetic information, ultimately contributing to cancer or
age-related pathologies. Indeed, DNA is constantly under assault and can be damaged
in a multitude of ways, including from replication-induced mismatches, chemicallyinduced crosslinks and adducts, base damage from ultraviolet light, and single- and
double-strand breaks resulting from ionizing radiation or chemical reactions (Ciccia and
Elledge, 2010). These DNA lesions affect the stability of the genome as well as impact
its ability to be accurately duplicated. In response to these lesions, cells have evolved
protective pathways that detect and repair damaged DNA, and pause cell cycle
progression to give cells time to resolve the problematic lesion (Blackford and Jackson,
2017). Defects in these pathways lead to the accumulation of DNA damage over time,
giving rise to an increased mutation burden that often results in age-related pathologies,
such as cancer (Tubbs and Nussenzweig, 2017). Understanding the essential
mechanisms at play during replication fork stabilization, collapse and repair in the
context of the genome, of the proteome and of the molecular signaling cascades, will
allow us to develop therapies for diseases induced by defects in replication and the
checkpoint response, such as cancer, Seckel syndrome and Fanconi anemia (Zeman
and Cimprich, 2014a).

2

DNA Replication
DNA replication is the process by which a doubled stranded DNA (dsDNA)
molecule is duplicated to produce an identical copy. This process is divided into three
phases: initiation, elongation and termination. Initiation occurs when the replicative DNA
helicase unwinds the origin of replication; during elongation the replication fork copies
the chromosome using semi-conservative DNA synthesis; and finally, termination results
when converging replication forks converge (Siddiqui, On and Diffley, 2013). Specific
regulation of the replication phases is crucial to assure accurate duplication of the
genome to prevent loss or amplification of genetic information. Indeed, replication
initiation is tightly controlled to ensure that the genome is only replicated once per cell
cycle (Diffley, 1996; Blow and Dutta, 2005). In this section, we will elaborate on the
sequence of events and factors involved in replication regulation.
Given that DNA replication must occur in approximately 6-12 hours in the
majority of mammalian cells and that replicative polymerases have a processivity of
approximately 1kb/min, origins spaced typically 50-150kb apart from one another must
be used to complete replication over the entire genome. These origins of replication are
mapped in bacteria and in yeast; however, mammalian origins of replication are not as
easily identified (Prioleau and MacAlpine, 2016). Scientists have sought to identify the
location of these origins for decades but it was not until recently that identification of
origin locations grew from a few dozen to over 100,000 through the use of genome-wide
technologies (Cadoret et al., 2008; Sequeira-Mendes et al., 2009; Mesner et al., 2011;
Besnard et al., 2012). Identifying origins has allowed the field to increase its
understanding of the genetic, epigenetic and proteomic features that characterize what
defines an origin and what regulates their distribution and usage during replication.
3

Though these findings are still in their infancy, many advances have been made in our
understanding of how the genetic sequence, chromatin milieu and nuclear architecture
influence the location, timing and activation of origins.
Initiation of DNA replication is comprised of two major steps: origin licensing
and origin firing. Origins are licensed in late mitosis and early G1 phases by loading the
pre-replicative complex (pre-RC) onto chromatin (Bell and Stillman, 1992; Remus et al.,
2009; Riera, Tognetti and Speck, 2014). The pre-RC complex is comprised of the origin
recognition complex (ORC) and the double hexameric minichromosome maintenance 27 (MCM2-7) helicase complex, that is recruited by CDC6 and the licensing factor CTD1
(Cvetic and Walter, 2006; Randell et al., 2006; You and Masai, 2008). A greater number
of origins are licensed than fired (Woodward et al., 2006). The unfired origins are termed
dormant origins and are only used to complete replication when the progression of a
nearby replication fork is compromised as a result of fork slowing, stalling or collapse
(Ge and Blow, 2010).
Origin firing occurs when the MCM2-7 helicases are activated in S phase to
begin the elongation phase of replication. These events are controlled through a cell
cycle mediated kinase signaling cascade, primarily regulated by DBF4-dependent kinase
(DDK) and cyclin-dependent kinase (CDK) (Heller et al., 2011; Tanaka and Araki, 2013).
CDK- and DDK-mediated recruitment of CDC45 and the GINS complex form the active
CMG (CDC45-MCM-GINS) helicase that is required for DNA synthesis (Aparicio et al.,
2009; Ilves et al., 2010; Fragkos et al., 2015). Other recruited proteins that are key
replisome components are Topoisomerase II binding protein 1 (TOPBP1), Treslin, and
the DNA polymerases (Kumagai et al., 2010, 2011; Boos et al., 2011; Yeeles et al.,
2015). Following helicase unwinding and initiation of DNA synthesis, additional
4

components of the replisome, such as TIMELESS, TIPIN and Claspin, will be recruited
(Gotter, Suppa and Emanuel, 2007; Yoshizawa-Sugata and Masai, 2007; Masai et al.,
2010). The ORC complex is removed from chromatin and degraded through ubiquitinmediated proteolysis to prevent another MCM helicase from being loaded onto the ORC,
which would lead to re-replication of that genomic loci (Méndez et al., 2002).
Once origins have fired and DNA synthesis is initiated, replication forks move in
opposite directions away from the origin. The helicase unwinds the duplex DNA,
separating the parental strands, each of which will be used as a template for DNA
synthesis (Masai et al., 2010). Replicative polymerases are proteins that synthesize
DNA in a 3’ to 5’ direction (Loeb and Monnat, 2008). Polymerase alpha initiates strand
synthesis, polymerase epsilon synthesizes DNA on the leading strand, and polymerase
delta synthesizes small stretches of DNA (Okazaki fragments) in between RNA primers
laid by primases on the lagging strand (Lujan, Williams and Kunkel, 2016). These
primers are eventually removed and Ligase 1 ligates Okazaki fragments to one another.
There are many other factors involved in DNA replication that contribute to faithful
genome replication and are adversely affected under conditions of replication stress. In
addition, it is hypothesized that the replisome composition is altered or modified under
different conditions of replication stress (Yoo et al., 2004; Mailand et al., 2006; Mamely
et al., 2006; Peschiaroli et al., 2006; Karlene A. Cimprich and Cortez, 2008; De Piccoli et
al., 2012). By using various proteomic techniques such as isolation of proteins on
nascent DNA (iPOND)-mass spectrometry (MS), we can better understand the
replication dynamics involved in the response to replication stress, as will be discussed
in this dissertation.
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Finally, replication termination occurs when two converging replication forks meet
or when a fork meets a chromatin end. The field has predominantly focused on
elucidating the mechanisms involved in replication initiation and elongation, leaving
much to still be understood about replication termination. During the process of
termination, the following steps occur in most organisms: replication fork convergence,
completion of DNA synthesis, replisome disassembly and decatenation (Dewar and
Walter, 2017). When replication forks encounter each other, their replisomes are
disassembled. Though this process has been shown to be mediated through ubiquitin
signaling and to involve the ubiquitin selective protein segregase p97, it remains to be
determined if the replisome is actively disassembled or not (Meerang et al., 2011). The
mechanism by which DNA synthesis is completed is also under debate. Some groups
argue that the single-stranded gap remaining between the leading stand and the last
Okazaki fragment is filled by the same mechanism utilized during elongation, whereas
other groups argue this process requires replisome disassembly (Dewar and Walter,
2017). Finally, catenated DNA is created by replicating the last turn of the parental
duplex DNA, which must be resolved before chromosome segregation. However, the
topological stress needs to be managed until chromosome segregation takes place,
leaving the field with important questions regarding the factors and pathways that are
involved in decatenation and relief of topological stress (Postow et al., 2001). If all
phases are successfully executed, the cell will have achieved complete and accurate
genome duplication, which it can pass on to the daughter cell.
However, as we will discuss, DNA replication can encounter numerous
obstacles, many of which are a result of replication stress. Fortunately, cells have
evolved intricate protective mechanisms, namely the DNA replication and DNA damage
6

checkpoints, that work to prevent these DNA replication perturbations from inducing
disease-causing genomic instability.
Replication stress
Replication stress is a problem that cells often face during DNA replication that
can have significant consequences on the stability of the genome, and ultimately, on cell
survival. DNA replication renders cells particularly susceptible to DNA lesions that can
block replication fork progression. Stalled forks can collapse into DSBs or be improperly
repaired, leading to a loss of genetic information that gives rise to many diseases, such
as cancer (Mcgowan, 2003; Paulsen and Cimprich, 2007). There is no uniform
description of replication stress nor unique cellular markers that specifically define this
phenomenon. As a result, the definition of replication stress is constantly evolving,
though some broad characteristics are agreed upon by the field. Generally, replication
stress is defined as the slowing or stalling of replication fork progression (Zeman and
Cimprich, 2014a). Though physical structures change depending on the lesion, all
replication stress-induced structures share a common feature: a tract of single-stranded
DNA (ssDNA). This tract is generated either from a functional uncoupling of the DNA
replicative helicase from the replicative polymerase, or from endonucleolytic processing
of DNA that resects the DNA strand where a nick or gap was left unrepaired, forming a
stretch of ssDNA. Prolonged exposure of ssDNA triggers the activation of the DNA
replication checkpoint pathway, the details of which will be discussed in the following
section (Byun et al., 2005; MacDougall et al., 2007).
Replication stress has both extracellular origins, such as exogenous DNA
damaging agents, and intracellular origins, such as impaired polymerase progression
through hard-to-replicate regions of the genome or DNA damaging agents generated
7

from metabolic and chemical reactions. Most exogenous sources of replication stress
arise from chemical mutagens and ultraviolet (UV) light that generate DNA lesions that
either block the helicase (e.g. DNA-topoisomerase adducts, intra-strand crosslinks, and
bulky DNA adducts), or that block polymerase progression, (e.g. base pair adducts,
polymerase inhibitors [such as aphidicolin], and chemicals [such as hydroxyurea] that
deplete deoxyribonucleotides [dNTP] pools) (Ciccia and Elledge, 2010). Limiting
exposure to these agents when it is possible should be a priority to prevent genomic
instability that could drive malignant transformation of cells.
There also exists a plethora of endogenous sources of replication stress that
cannot be mitigated by limiting exposure; instead, DNA damage repair pathways have
naturally evolved to resolve these inevitable lesions. Ironically, nicks and gaps are
naturally-occurring intermediates in many DNA repair pathways and if encountered by
replication machinery, will stall the forks, eventually causing them to collapse. Though it
remains controversial whether or not nicks and gaps behind the fork can cause fork
stalling, nicks and gaps ahead of the replication fork can collapse into DSBs through
duplex unwinding. Indeed, a nick or gap on the leading strand will cause the helicase to
slide off the DNA, leading to fork collapse, and a nick or gap on the lagging strand could
result in fork progression problems that cause fork stalling. Many unrepaired DNA
lesions, such as inter-strand crosslinks and protein-DNA crosslinks that can be caused
by metabolic pathway products (e.g. reactive aldehydes generated during alcohol
metabolism) can also be barriers to replication fork progression (Mirkin and Mirkin, 2007;
Dalgaard JZ, 2011).
Another

cause

of

replication

stress

results

from

misincorporation

of

ribonucleotides in DNA (Williams, Lujan and Kunkel, 2016). DNA replicative
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polymerases faithfully match base pairs but are less specific at discriminating between
dNTPs and ribonucleotides, which they surprisingly often incorporate erroneously
(Dalgaard, 2012). This replication defect is recognized and corrected through the
ribonucleotide excision repair pathway (Reijns et al., 2012; Sparks et al., 2012). If not
removed, the incorporated ribonucleotide will stall the polymerase and the DNA damage
tolerance pathway will be required to bypass the lesion (Anglana et al., 2003; Nick
McElhinny et al., 2010; Lazzaro et al., 2012).
DNA replication requires many different components to be successfully
completed, so when any are limiting, it can lead to polymerase slowing and eventual fork
stalling (Poli et al., 2012; Sørensen and Syljuåsen, 2012). Some well characterized
insufficiencies are those of nucleotides and replisome factors. Depletion of these factors
often result from aberrant regulation of replication initiation leading to an excess of origin
firing that overwhelm the existing pools of factors (Beck et al., 2012). It has been well
documented that overexpression or constitutive activation of oncogenes, such as RAS,
MYC or cyclin E, lead to increased origin firing, resulting in insufficient nucleotide levels
or increased collision with transcriptional machinery (Halazonetis, Gorgoulis and Bartek,
2008; Bester et al., 2011; Jones et al., 2012; Burrell et al., 2013).
Because replication and transcription machinery are both active during S phase
and share the same substrate, they inevitably interfere with one another (Helmrich et al.,
2013). It has been reported that collision with the transcription complexes and RNA-DNA
hybrid structures known as R loops causes replication stress (Bermejo, Lai and Foiani,
2012). This is supported by findings that identified “early replicating fragile sites” that are
found in highly transcribed genomic regions, which have a high incidence of DSB
formation (Barlow et al., 2013). In addition, many studies using various visualization
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techniques, including DNA combing and electron microscopy, have established that
encounters between the transcription and replication complexes cause replication stress
and eventual DNA damage (Paulsen et al., 2009; Wahba et al., 2011; Stirling et al.,
2012). DNA damage induced by replication-transcription interference is a consequence
of either R loop formation or resulting topological stress (García-Muse and Aguilera,
2016). R loops occur when RNA polymerases pause due to secondary DNA structures
or collide with the replication fork (Aguilera and García-Muse, 2012). Topological stress
occurs when a replication fork approaches a transcribed region that cannot rotate freely,
such as when it is tethered to the nuclear periphery (Bermejo et al., 2011). If the region
is not detached from the nuclear pore, accumulation of positive supercoiling in front of
the fork will result in fork collapse and fork reversal (Bermejo et al., 2011).
Finally, intrinsically difficult to replicate DNA sequences exist in the genome,
such as secondary structure-forming DNA, DNA repeats, and common fragile sites
(CFS), that pose a challenge to replication progression and that are associated with
increased chromosomal rearrangements. CFS are defined genomic sites that display
increased sensitivity to replication stress and, as visualized by metaphase spreads, are
prone to breaking under conditions of replication stress (Casper et al., 2002; Glover,
Wilson and Arlt, 2017). The only unifying features between the different CFS are their
megabase-spanning large size, their late replication timing in S phase, the presence of
genes larger than 300kb in size, and their disposition to replication stress-induced
breakage (Glover et al., 2005; Debatisse et al., 2012). All of these features have been
proposed to contribute to CFS fragility though the reasons for their fragility is still under
debate. One hypothesis is that because CFS carry very long genes, which take a long
time to transcribe, the DSBs found at these sites result from collision of the replication
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and transcription machinery (Helmrich et al., 2013). However, because CFS fragility
does not correlate with the expression of these genes in some cell lines and the rate of
the replication fork is unperturbed, this hypothesis is unlikely (Le Tallec et al., 2013).
Another explanation of CFS fragility is their paucity of replication origins, preventing the
ability of stalled forks to be rescued by replication initiation at other origins (Letessier et
al., 2011). The fact that CFS replicate in late S phase exacerbates this problem as
dormant origins in areas surrounding CFS have a limited amount of time to initiate and
complete replication. As these incompletely replicated genomic loci enter mitosis, the
resulting aberrant replication intermediates are processed by nucleases, such as Mus81Eme1 or ERCC1, resulting in DSBs and promoting disease-inducing genomic instability
(Naim et al., 2013; Ying et al., 2013). Many deletions and chromosomal rearrangements
found in cancers occur at these CFS, supporting their contribution to cancer-causing
genome instability (Bignell et al., 2010).
DNA repeats, such as trinucleotide repeats, short and long interspersed nuclear
elements (SINEs and LINEs, respectively), and long terminal repeats (LTRs) also
perturb DNA replication. A majority of the human genome is comprised of repetitive
elements, some of which are remnants of viral sequence insertions during our evolution
(Griffiths, 2001; Wildschutte et al., 2016). Indeed, retroelements, such as LINEs and
SINEs, can become increasingly transcribed during conditions of replication stress and
insert themselves in genomic loci prone to instability, further promoting instability
(Gualtieri et al., 2013; Mourier et al., 2014; Zaratiegui, 2017). Additionally, long stretches
of repeats promote replication polymerase slippage, which can lead to the expansion or
contraction of these repeats, causing gene dysfunction (McMurray, 2010; Kim and
Mirkin, 2013). When expanded, several trinucleotide repeats (CGG, GAA, CTG) result in
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genetic instability and are associated and contribute to the pathology of diseases such
as Fragile X syndrome, Friedreich’s ataxia and Myotonic dystrophy (Castel, Cleary and
Pearson, 2010; Mirkin and Mirkin, 2014; Jones, Houlden and Tabrizi, 2017).
Finally, secondary structure-forming DNA are known to cause replication stress.
Some of these sequences include the aforementioned tandem trinucleotide repeats,
which can form hairpins or triplexes that can block fork progression. Recently, our
laboratory has discovered additional hard-to-replicate tandem repeats that can cause
secondary structures and that were shown to stall or collapse replication forks (Shastri,
Tsai et al., under revision). G-quadruplexes are secondary structures that form from GCrich DNA sequences (Técher et al., 2017). Structural stabilization of G-quadruplexes by
chemical means or loss of the helicases required to unwind them increase DSB
formation and cause a loss of genetic information at those sites (Bochman, Paeschke
and Zakian, 2012; Paeschke et al., 2013).
As discussed, there are many endogenous and exogenous sources of replication
stress and more are still being discovered. In addition, levels of replication stress, as well
as the source of stress, appear to elicit varying cellular responses as well as different
patterns of genomic lesions and instability. Exposure to replication stress will activate the
DNA replication checkpoint response to overcome these stresses and protect genomic
integrity. Yet much remains to be elucidated when it comes to understanding how the
cell copes with these different conditions and in particular which mechanisms are
essential under different conditions, as will be discussed in Chapter 3.
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DNA Replication Checkpoint
To ensure genomic stability, cells have evolved detection and repair mechanisms
that monitor DNA lesions and coordinate repair with cell-cycle progression (Blackford
and Jackson, 2017). Indeed, cell cycle checkpoints control cell cycle progression and
allow cells to pause the cell cycle to provide time for DNA damage to be repaired before
cell division resumes (Zhou et al., 2000; Kastan and Bartek, 2004a). If the damage
cannot be resolved, checkpoint activation can trigger permanent cell cycle arrest
(senescence) or cause cells to undergo programmed cell death (apoptosis) to prevent
propagation of the mutated cell (Branzei and Foiani, 2009; Sperka, Wang and Rudolph,
2012). Once DNA damage is recognized by the cell, cellular signaling cascades are
triggered to promote DNA repair. Different types of DNA damage activate cell cycle
checkpoint pathways that regulate distinct repair mechanisms. More specifically,
physical DNA lesions, such as DSBs, will trigger the ataxia telangiectasia mutated (ATM)
and the DNA-dependent protein kinase (DNA-PK) kinase-regulated DNA damage
checkpoint, whereas DNA replication stress will activate the ataxia telangiectasia and
Rad3-related protein (ATR)-regulated DNA replication checkpoint (Maréchal and Zou,
2013; Blackford and Jackson, 2017). These signaling cascades will activate many
downstream effector proteins as well as other cellular responses to mediate repair,
ultimately resolving the DNA damage and resuming cell cycle progression.
DNA replication checkpoint activation occurs in S phase and is essential to
ensure faithful duplication of the genome. As discussed previously, this checkpoint is
activated by replication stress, usually triggered by impediments that block DNA
replication fork progression and is regulated by ATR, a phophoinositide 3-kinase-related
kinase (PIKK). ATR was originally discovered as an essential budding yeast gene
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through screens for S and G2 checkpoint defects and screens for hypersensitivity to
hydroxyurea and methyl methanesulfonate (Allen et al., 1994; Kato and Ogawa, 1994;
Weinert, Kiser and Hartwell, 1994). The human gene was later cloned revealing its PIKK
domain, adding it to the PIKK protein family along with ATM and DNA-PK (Bentley et al.,
1996; Cimprich et al., 1996). However, unlike ATM and DNA-PK, ATR is essential for
embryonic development and crucial for genomic integrity (E. J. Brown & Baltimore, 2003;
E J Brown & Baltimore, 2000).
Many types of DNA replication fork obstructions can cause replication stress and
activate ATR but they all share a similar resulting DNA structure at the fork, which
consists of single-stranded DNA (ssDNA) (MacDougall et al., 2007). The unwinding
minichromosome maintenance (MCM) helicase, but not the DNA replicative polymerase,
can overcome most DNA lesions leading to their uncoupling. This results in an
accumulation of ssDNA between the helicase and the polymerase, which is rapidly
coated by the ssDNA-binding protein complex, replication protein A (RPA) (Byun et al.,
2005). The tract of ssDNA can further be expanded by exonucleases. In addition to
ssDNA tracts being formed from uncoupling of the helicase and polymerase, ssDNA
tract can be generated by endonucleolytic processing of other forms of DNA lesions
(Raderschall, Golub and Haaf, 1999). The RPA-ssDNA complex then serves as a
platform to recruit the ATR-interacting protein (ATRIP), which is required for the
interaction of ATR with the stalled replication fork but not sufficient for ATR activation at
the fork (Cortez et al., 2001; Zou and Elledge, 2003; Ball, Myers and Cortez, 2005; Kim
et al., 2005; Namiki and Zou, 2006).
Two proteins have been shown to be required to stimulate ATR activation,
topoisomerase II binding protein 1 (TOPBP1) and Ewing tumour-associated antigen 1
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(ETAA1). TOPBP1 is recruited to the to the ATR-ATRIP complex by a ssDNA-doublestranded DNA (dsDNA) junction (Michael et al., 2000; Ellison and Stillman, 2003;
Bomgarden et al., 2004; Kumagai et al., 2006; MacDougall et al., 2007; Mordes et al.,
2008). This junction is also necessary for the loading of the RAD9-RAD1-HUS1 (9-1-1)
checkpoint clamp complex by the RAD17/RFC2-5 clamp loader complex (Bermudez et
al., 2003; Delacroix et al., 2007; Lee, Kumagai and Dunphy, 2007; Navadgi-Patil and
Burgers, 2009). Once the 9-1-1 clamp is loaded on the ssDNA-dsDNA junction, it
recruits TOPBP1 to the ATR-ATRIP-RPA coated ssDNA in conjunction with the MRE11RAD50-NBS1 (MRN) complex and RAD9-RAD1-HUS1-interacting nuclear orphan
(RHINO), although the mechanisms by which the MRN complex and RHINO contribute
to TOPBP1 recruitment remain elusive (Cotta-Ramusino et al., 2011; Duursma et al.,
2013; Lee and Dunphy, 2013; Lindsey-Boltz et al., 2015). Once TOPBP1 is recruited, it
interacts with the ATR-ATRIP complex through its ATR activation domain, which
interacts with ATR to activate it. The second, and recently identified, ATR activator is
ETAA1, which like TOPBP1 contains an ATR-activation domain but unlike TOPBP1
interacts with the RPA-ssDNA platform through direct binding of RPA (Bass et al., 2016;
Feng et al., 2016; Haahr et al., 2016). It remains to be determined if these activators
recognize different ssDNA structures that require distinct repair signaling pathways to be
resolved, possibly dictated through a specificity in downstream substrates of ATR. Once
activated, ATR can phosphorylate its multitude of effector proteins to trigger signaling
cascades that promote DNA repair by modulating many cellular processes and by
coordinating cell cycle, DNA repair and DNA replication.
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The functions of ATR in DNA replication and repair
Once activated, ATR stimulates multiple signaling cascades that protect genomic
integrity by halting cell cycle progression, limiting firing of novel origins of replication,
stabilizing the replication fork, and promoting replication fork repair and restart (Saldivar,
Cortez and Cimprich, 2017).
ATR prevents cell cycle progression
By coordinating cell cycle arrest with replication, ATR prevents cells from
entering prematurely into mitosis before replication defects are resolved and before
replication is complete. ATR exerts its checkpoint function on the cell cycle primarily
through its most prominent and well-characterized downstream effector, the checkpoint
kinase 1 (CHK1) (Guo et al., 2000; Hekmat-Nejad et al., 2000; Liu et al., 2000; Zhao and
Piwnica-Worms, 2001). ATR activates CHK1 by phosphorylating its serine 317 and 345
sites. The interaction between ATR and CHK1 is facilitated by Claspin, an adaptor
protein localized at the fork (Kumagai and Dunphy, 2000; Liu et al., 2000; Zhao and
Piwnica-Worms, 2001; Liu, Song and Zou, 2012). It has also been suggested that the
timeless (TIM) and timeless-interacting protein (Tipin) complex might be involved in ATR
activation of CHK1 through its recruitment to stalled forks. Indeed, TIM and Tipin loss
lead to a decrease in the ability of ATR to activate CHK1 (Chou and Elledge, 2006;
Errico, Costanzo and Hunt, 2007; Unsal-Kaçmaz et al., 2007; Yoshizawa-Sugata and
Masai, 2007; Smith, Fu and Brown, 2009). Once phosphorylated at the fork, CHK1 is
released from chromatin to carry out its DNA damage response signaling to the rest of
the nucleus.
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CHK1 controls cell cycle progression by phosphorylating the three CDC25
phosphatases, ultimately leading to their degradation or sequestration (Löffler et al.,
2006). The CDC25 phosphatases remove the inhibitory phosphorylation of the cyclindependent kinases (CDKs). Therefore, CHK1-dependent inactivation of the CDC25
proteins prevents CDK activation and premature entry into mitosis (Piwnica-Worms et
al., 1998). CHK1 phosphorylation of CDC25A triggers its ubiquitin-mediated degradation,
facilitated by the SCFβ-TRCP E3 ubiquitin ligase complex (Busino et al., 2003; Jin et al.,
2003). CDC25A degradation prevents CDK1 activation to inhibit entry into mitosis and
prevents CDK2 activation to prevent origin firing (Chen, Ryan and Piwnica-Worms,
2003a). CHK1 also phosphorylates CDC25C, resulting in 14-3-3 binding and
sequestration to the cytoplasm, which prevents CDK1 activation (Kasahara et al., 2010).
These events provide cells with sufficient time to respond to replication perturbations
and finish replication before entry into mitosis.
ATR inhibits novel origin firing
The ATR-CHK1 axis also inhibits global origin firing under conditions of
replication stress to prevent additional fork stalling until the stress is resolved (Diffley and
Santocanale, 1998; Costanzo et al., 2003; Karnani and Dutta, 2011; Yekezare, GomezGonzalez and Diffley, 2013). ATR limits origin firing by preventing replication initiation by
blocking activation of the MCM2-7 helicase. Helicase activation requires the loading of
the pre-initiation complex, which is comprised of many factors, including CDC45, Treslin,
the GINS complex and other replisome components. CDC45 binding for helicase
activation depends on phosphorylation of Treslin by CDK2 and by phosphorylation of the
MCM2-7 helicase by DBF4-dependent kinase (DDK) (Deegan, Yeeles and Diffley,
2016). Therefore, CDK2 and DDK inhibition prevents CDC45 loading, MCM2-7
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activation and origin firing. The CHK1 yeast homologue was shown to phosphorylate
Dbf4 to suppress DDK activity and ATR was shown to phosphorylate DDK in human
cells, though this site was not shown to affect DDK activity. Further studies are required
to determine if the ATR-CHK1 checkpoint can inhibit DDK-dependent CDC45 loading
and origin firing (Heffernan et al., 2007; Zegerman and Diffley, 2010). In addition, CHK1
prevents origin firing through CDC25A degradation resulting in CDK2 inhibition thus
preventing CDC45 loading (Mailand et al., 2000; Zhao, Watkins and Piwnica-Worms,
2002). Finally, CDC45 loading and origin firing was shown to be suppressed by CHK1mediated phosphorylation of Treslin, which could be another mechanism by which the
ATR-CHK1 axis controls origin firing (Guo et al., 2015). Of note, the ATR-CHK1
checkpoint prevents origin firing globally but interestingly allows local origin firing (Diffley,
1996; Ge and Blow, 2010). These functions that initially appear at odds with one another
actually promote genomic stability by allowing local dormant origins to fire to ensure
complete replication in the region surrounding the stall site but prevent global and latereplicating origins from firing to avoid stalling of additional replication forks until the
replication stress-inducing event is resolved. The mechanism by which local origins
evade checkpoint suppression of origin firing remains to be elucidated; however, some
evidence suggests that CDC45 might already be loaded onto local dormant origins in the
replication problematic area thereby bypassing the step inhibited by the checkpoint
(Thomson, Gillespie and Blow, 2010).
ATR controls dNTP levels
ATR also preserves genomic stability by preventing additional replication fork
stalling events by inhibiting additional replication stress-inducing stressors, such as
nucleotide insufficiency. Indeed, it was originally thought that safeguarding adequate
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levels of nucleotides was ATR’s primary genome-protecting function from studies in
budding yeast, where lethality resulting from ATR homologue loss could be rescued by
overexpressing ribonucleotide reductase (Rnr), the enzyme responsible for dNTP
production (Huang, Zhou and Elledge, 1998; Zhao, Muller and Rothstein, 1998). In
human, ATR is required for ribonucleoside-diphosphate reductase subunit M2 (RRM2)
expression and to prevent its CDK-cyclin F mediated degradation (Zhang et al., 2009;
D’Angiolella et al., 2012). Finally, mice carrying a hypomorphic mutation of ATR
exhibited prolonged survival and reduced levels of genomic instability when crossed to
mice expressing supra-physiological levels of RRM2 (Lopez-Contreras et al., 2015).
Though sometimes overlooked, ATR’s function in maintaining replication-favorable
levels of dNTPs is key in maintaining genomic stability.
ATR stabilizes stalled replication forks
In addition to its regulatory roles in cell cycle, origin firing and nucleotide levels,
ATR is best known for its replication fork stabilizing functions. By stabilizing replication
forks, ATR prevents stalled forks from collapsing into DSBs and allows them to reinitiate
replication once the stalling agent has been eliminated (Lopes et al., 2001; Tercero and
Diffley, 2001). Indeed, ATR loss has been shown to increase levels of genomic instability
as measured by elevated levels of DSBs and fork-associated recombination structures,
such as reversed forks (E J Brown & Baltimore, 2000; Eric J Brown & Baltimore, 2003;
Myung, Datta, & Kolodner, 2001). The mechanism by which this occurs has been under
fierce debate in the field and many models have been proposed.
The first model suggests that fork collapse, as defined by the inability to restart
replication, results from premature replisome disassociation (Cobb et al., 2005). ATR
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phosphorylates many replisome components under condition of replication stress,
including DNA polymerases, the MCM2-7 helicase, the clamp loader RFC1-5 and the
Claspin-timeless-tipin-AND1 complex (Block, Yu and Lees-Miller, 2004; Cortez, Glick
and Elledge, 2004; Olson et al., 2006; Göhler et al., 2011). In addition, many replisome
factors, such as FANCM and Claspin, are targeted for degradation following extended
fork stalling (Yoo et al., 2004; Mailand et al., 2006; Mamely et al., 2006; Peschiaroli et
al., 2006; Kee et al., 2009). Finally, our laboratory has observed decreased levels of
replisome components under conditions of replication stress in ATR-depleted cells and
showed that suppression of RNF4, PLK1 or AURKA, which are involved in degradation
pathways, rescues the replication restart defect seen in ATR-depleted cells (Ragland et
al., 2013). Together these data suggest that removal of components required for
replication prevent the replication of restart once forks stall. Though there are studies
supporting this model, recent genomic and proteomic data have contested this model
(De Piccoli et al., 2012; Dungrawala et al., 2015). More studies are needed to better
define in which context (cell cycle phase, organism, replication stress, etc) this model
might be applicable.
A second model of fork stabilization proposes that fork collapse is driven by
nucleolytic enzymes that recognize and cleave specific structures formed at stalled or
processed forks (Alessandra Pepe and West, 2014a). Though direct regulation of
structure-specific nucleases by ATR has yet to be shown, it is possible that ATR
regulates fork remodeling processes, such as fork reversal. Indeed, the DNA annealing
helicases and fork reversal enzyme SMARCAL1 is a substrate of ATR and once
phosphorylated, SMARCAL1 displays reduced ability to reverse forks (Couch et al.,
2013a). The resulting reversed fork structures are susceptible to cleavage by structure20

specific endonuclease subunit SLX4 in complex with several structure-specific
nucleases, such as SLX1, MUS81-EME1 and XPF-ERCC1 (Cotta-Ramusino et al.,
2005; Hanada et al., 2007; Forment et al., 2011; Wyatt et al., 2013a, 2017; Duda et al.,
2016). In support of this model are studies that show that loss of SLX4 decreases DSB
formation in ATR-inhibited cells (Couch et al., 2013a; Ragland et al., 2013). Of note,
ATR’s role in protecting forks from nuclease-dependent fork collapse is also reinforced
by its indirect inhibition of CDK as some of the structure-specific endonuclease are
activated by CDK (Domínguez-Kelly et al., 2011). Indeed, in the absence of ATR, CDK
levels are not regulated under conditions of replication stress, and nucleases are
prematurely activated causing cleavage-induced fork collapse.
In line with this second model, it is also possible that DSB formation from fork
collapse might actually be an intermediate generated during a process of homologous
recombination (HR)-mediated replication restart. It was recently shown that the S phase
specific endonuclease MUS81-EME2 is responsible for fork cleavage of stalled
replication forks to allow for replication restart (Alessandra Pepe and West, 2014a).
Therefore, it is possible that nuclease-dependent stalled fork cleavage is an attempt at
replication restart in ATR-depleted cells.
A third model is that ATR stabilizes forks by regulating pathways that promote
replication fork restart, such as template switching, DNA damage tolerance pathways,
and HR-mediated fork restart. Indeed, ATR phosphorylates translesion polymerases,
reversionless 1 (REV1) and Pol h, proposing that ATR allows DNA lesion bypass
(Göhler et al., 2011; Sale, 2013). Additionally, many players in restart pathway, such as
HR and template switching, are substrates of ATR and are necessary for RAD51
recruitment to stalled and collapse forks, suggesting that ATR might regulate RAD5121

dependent restart-promoting pathways (Vassin et al., 2009; Murphy et al., 2014; Ahlskog
et al., 2016; Buisson et al., 2017). Finally, ATR could protect forks by promoting
replication restart by processing repair intermediates through the regulation of
recombination repair factors, such as the BLM and WRN helicases, which are ATR
substrates and involved in fork restart to prevent collapse (Davies et al., 2004;
Ammazzalorso et al., 2010).
A final model has proposed that ATR stabilizes forks indirectly by preventing the
exhaustion of RPA. Under conditions of replication stress and ATR inhibition, an excess
of ssDNA is generated exceeding the amount of RPA available to coat it, thereby
rendering the uncovered forks susceptible to nuclease cleavage (Toledo et al., 2013;
Toledo, Neelsen and Lukas, 2017). More studies are needed to build a stronger case for
this model though it is not difficult to imagine that an insufficiency of protective factors
could play an important role in triggering increased fork collapse after fork stalling.
Every model is backed by convincing experimental data and no model excludes
the other so it is possible that the mechanism of fork stabilization by ATR might be
context dependent or a combination of the different models. Additional studies will help
further clarify the mechanism(s) by which ATR stabilizes replication forks and which of
its functions are crucial for its fork stabilizing role (Chapter 3).
Repair of collapsed replication forks
Collapsed forks are defined as stalled forks unable to resume replication, and
occur when ATR is unable to stabilize stalled forks or under conditions of prolonged
replication stress. To repair a collapsed fork, it must often transition through a DSB
structure intermediate. Many studies have shown that collapsed fork structures are
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substrates of structure-specific nucleases that process them in DSBs (Fekairi et al.,
2009; Couch et al., 2013a; Ragland et al., 2013; Szakal and Branzei, 2013a; Wyatt et
al., 2013a; Sarbajna, Davies and West, 2014). Indeed, MUS81-EME2 is a nuclease
complex that is only active in S phase and that is required for fork restart by cleaving the
fork to induce DSB formation (Alessandra Pepe and West, 2014a). In the absence of the
ATR-regulated checkpoint, aberrant CDK signaling promotes premature activation of
G2/M nucleases, such as SLX4-SLX1 and MUS81-EME1, which process the
unprotected fork into a DSB (Couch et al., 2013a; Ragland et al., 2013).
Once DSBs are formed, the ATM-CHK2-regulated DNA damage checkpoint
pathway is activated. DSB repair occurs by homologous recombination, which uses the
sister chromatid as a DNA template to prevent loss of genetic information (West, 2003).
The DSB is resected by the MRN complex at the 5’ end, recruiting ATM, and generating
RPA-coated ssDNA overhangs (Lamarche, Orazio and Weitzman, 2010). Following its
activation via autophosphorylation, ATM phosphorylates its substrates, among which are
the H2AX histone variant and the CHK2 kinase (Rogakou et al., 1998; Matsuoka et al.,
2000). Phosphorylated H2AX, gH2AX, regulates the repair process and CHK2 arrests
the cell cycle (Paull et al., 2000; Kuo and Yang, 2008; Chanoux et al., 2009). Of note,
under conditions of replication stress, ATR will also phosphorylate H2AX (Ward and
Chen, 2001). gH2AX acts as a surrogate marker of DSB and recruits repair factors at the
lesion. gH2AX spreads along the chromatin up to several hundreds of kilobases on either
end of the break, either as a means to remodel the chromatin to enhance repair protein
recruitment and accessibility to the site, or to prevent transcription-replication collision
and formation of R loops because gH2AX-marked chromatin is transcriptionally silenced
(Rogakou et al., 1999; Chou et al., 2010; Polo et al., 2012; Britton et al., 2014). Together
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with the MDC1 adaptor protein, gH2AX recruits the RNF8 and RNF168 E3 ubiquitin
ligases, which promote the ubiquitin-mediated recruitment of the BRCA1-RAP80
complex in a CtIP-dependent manner (Stucki et al., 2005; Shao et al., 2009; Ohta, Sato
and Wu, 2011; Strauss and Goldberg, 2011). Following extended resection by MRN in
coordination with BLM helicase and EXO1 or DNA2 nucleases, BRCA1 will then recruit
BRCA2 via PALB2, which will mediate RAD51 loading onto the resected ssDNA
overhangs, displacing RPA to form RAD51 filaments (Sy, Huen and Chen, 2009;
Peterson et al., 2011). RAD51 orchestrates strand exchange via D-loop formation and
homologous recombination ensues to complete the repair (Liu et al., 2010). Once the
DSB is repaired, replication can continue and be completed by novel origin firing or by a
nearby actively replicating fork.
G2-M cell cycle kinases
CDK-cyclin control of cell cycle
The cell cycle is a tightly regulated process that ensures genome duplication and
cell division, which is controlled by mitogenic signaling and the pathways discussed
previously that monitor DNA integrity. Cell cycle is comprised for four cell cycle phases
(G0/G1, S, G2, M) that are coordinated by several cyclin-dependent kinases (CDKs) in
complex with their cyclin partners whose expression levels cycle (hence their name)
through the cell cycle (Murray, 2004). Different CDK-cyclin complexes and pathways
control entry into each phase (Malumbres and Barbacid, 2009). Briefly, CDK4/6-cyclin D
and CDK2-cyclin E are sequentially needed to have cells enter the cell cycle from a state
of quiescence following mitogenic stimulation. These complexes in turn phosphorylate
and inactivate the tumor suppressor protein retinoblastroma (Rb), which leads to the
activation of the E2F-dependent transcriptional program that promotes S phase entry
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(Giacinti and Giordano, 2006). Progression through S phase is regulated by CDK2-cyclin
E as well as CDK2-cyclin A in S phase and CDK1-cyclin A in G2. Finally, the CDK1cyclin B complex drives cells into mitosis followed by cell division (Norbury and Nurse,
1992; Weinberg, 1995; Murray, 2004). We will focus on the players involved in entry into
G2-M phase and their role in cancer.
Regulation of CDK1
CDK1 is the only CDK that is essential for cell cycle progression as it can
compensate for the loss of all other cell cycle CDKs (CDK2, CDK4 and CDK6)
(Santamaria and Ortega, 2006). As mentioned above, CDK1 is required for entry into
mitosis and needs to be inactivated for cells to exit mitosis. In late mitosis, CDK1 is
inactivated through proteasome-mediated degradation of cyclin B by the anaphasepromoting complex/cyclosome (APC/C) complex to promote mitotic exit (Gavet and
Pines, 2010). Once CDK1 is inactive, cells can separate their chromosomes and
undergo cytokinesis.
Cyclin levels are not the only regulators of CDKs. CDKs are also regulated by
their phosphorylation levels. CDK1 is inactivated when phosphorylated at its Thr14 and
Tyr15 sites by membrane associated tyrosine- and threonine-specific cdc2-inhibitory
kinase (MYT) and WEE1, respectively, and it is activated by removal of these
phosphates by the CDC25 phosphatases (Parker and Piwnica-Worms, 1992; Mueller et
al., 1995).
Regulation of the Aurora A- PLK1 pathway
The Aurora A (AURKA) and Polo-like kinase (PLK1) kinases carry out many
functions in mitosis, such as centrosome maturation, bipolar spindle assembly and
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chromosomal segregation, but our focus will be on their role and regulation in the
context of cell cycle progression and entry into mitosis (Asteriti, De Mattia and
Guarguaglini, 2015).
Aurora A is a serine-threonine kinase that is first expressed in late S phase
(Walter et al., 2000; Seki, Coppinger and Jang, 2008). Aurora A kinase promotes mitotic
entry through phosphorylation and activation of the serine-threonine kinase PLK1
(Macůrek et al., 2008). Indeed, PLK1 activates the CDK1-cyclin B complex by activating
the CDC25C phosphatase which activates CDK1, as well as by inducing the degradation
of WEE1, the negative regulator of CDK1 (Nigg, 2001; Seki, Coppinger and Jang, 2008;
S. M. a Lens, Voest and Medema, 2010). The CDK1-AURKA-PLK1 mitotic entry
pathway is regarded as a switch, which once activated is difficult to inhibit. Once the
CDK1, Aurora A and PLK1 kinases are activated, they enter into a positive feedback
loop that ultimately irreversibly drives mitotic entry (Seki, Coppinger and Jang, 2008;
Seki, Coppinger, Du, et al., 2008; Feine et al., 2014).
Aurora A has an autophosphorylation site on its activation loop at conserved
residue Thr288, which was thought to be a mark of activation until a recent study
showed that it was possible for Aurora A to be autophosphorylated and not be active
(Bischoff et al., 1998; Walter et al., 2000; Littlepage et al., 2002; Bayliss et al., 2003a;
Eyers et al., 2003; Haydon et al., 2003; Hirota et al., 2003a; Elena N. Pugacheva and
Golemis, 2005; Seki, Coppinger and Jang, 2008; Moore et al., 2010; Molli et al., 2010;
Huang et al., 2011; Dodson and Bayliss, 2012a). Aurora A requires binding partners for
enhanced activity, which are thought to dictate Aurora A substrate specificity and cellular
localization (S. M. a Lens, Voest and Medema, 2010). In addition to these roles, binding
of these partner proteins to Aurora A influences its activity and stability (1) by promoting
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Aurora A autophosphorylation, (2) by shielding the autophosphorylation site from
phosphatases through conformational change, and (3) by inhibiting Aurora A recognition
by the ubiquitin E3 ligase APC/C with its co-activator Cdh1 (APC/CCdh1). Two wellcharacterized Aurora A binding proteins are Bora and TPX2 (Kufer et al., 2002a; Eyers
et al., 2003; Eyers and Maller, 2004; Hutterer, Berdnik, Wirtz-Peitz, Zigman, et al., 2006;
Seki, Coppinger, Jang, et al., 2008; Bruinsma et al., 2014a). Bora localizes Aurora A in
the nucleoplasm and plays an essential role in driving the G2/M transition by promoting
Aurora A-mediated activation of PLK1 (Seki, Coppinger and Jang, 2008). TPX2 localizes
Aurora A to mitotic spindles after nuclear envelope break down and protects Aurora A
dephosphorylation at its Thr288 site by inducing a conformational change in its activation
loop (Kufer et al., 2002a; Bayliss et al., 2003a; Eyers et al., 2003; Li, Cao and Zheng,
2003; Tsai et al., 2003a; Eyers and Maller, 2004; Dodson and Bayliss, 2012b). Aurora A
is known to interact with several other binding proteins, including HEF1, PAK1, Arpc1b,
and PUM2, which aid Aurora A with its other functions (Elena N. Pugacheva and
Golemis, 2005; Zhao et al., 2005; Molli et al., 2010; Huang et al., 2011).
Interestingly, the AURKA-PLK1 pathway regulates itself. Aurora A activates
PLK1, which in turn is responsible for Aurora A degradation to drive mitotic exit and
cytokinesis (Barr, 2004; Chan et al., 2008a; van Leuken et al., 2009; S. M. a Lens, Voest
and Medema, 2010). Proteolytic degradation of Aurora A is tightly regulated by
APC/CCdh1 (van Leuken et al., 2009). In late anaphase, the APC/CCdh1 recognizes the
degradation box (D-box) of Aurora A and a lack of phosphorylation at its Ser51 site in its
A-box, leading to its proteasome-mediated degradation (Dutertre, Descamps and
Prigent, 2002; Littlepage and Ruderman, 2002a; S. M. a Lens, Voest and Medema,
2010). PLK1 also controls Aurora A localization and function by regulating its binding
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partners (Chan et al., 2008b). Indeed, PLK1 regulates Aurora A binding partner
preference, which in turn regulates its localization and function, through b-TRCPdependent Bora degradation.
The AURKA-PLK1 pathway is important for recovery after DNA damage. Indeed,
PLK1 is required for mitotic entry following G2 cell cycle arrest induced by DNA damage
(van Vugt, Brás and Medema, 2004; Peng, 2013; Hyun et al., 2014). PLK1 also
regulates the activation of MUS81-EME1 and stimulates its association with the SLX4
endonuclease complex, promoting replication restart through DSB generation at stalled
replication forks (Matos et al., 2011; Gallo-Fernández et al., 2012; Muñoz-Galván et al.,
2012; Szakal and Branzei, 2013a). Due to its prominent and impactful role in the cell
cycle and in the checkpoint pathways, it is not surprising that the AURKA-PLK1 pathway
is tightly regulated in various ways, such as by stabilization, degradation, localization,
phosphorylation and partner protein interaction.
Cell cycle: a target of DDR
Under conditions of DNA damage, cell cycle checkpoints are activated to block
cell cycle progression and allow time for DNA repair. As we previously discussed, the
DNA damage checkpoints achieve cell cycle control through modulation of CDK activity.
CHK1 phosphorylation inactivates the CDC25 phosphatases and activates WEE1 kinase
to inhibit CDK1 and CDK2, forcing cells to arrest in G2 phase. In addition, the AURKAPLK1 pathway is similarly inhibited during the checkpoint to prevent premature entry into
mitosis (Parrilla et al., 2016; Bruinsma et al., 2017)
Cell cycle dysregulation in cancer
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Cancer can be defined as uncontrolled cell proliferation that results from
unregulated cell cycle activity, caused either by mutations in signaling pathways or in
genes coding for cell cycle proteins. CDKs are frequently dysregulated in cancers,
making them a therapeutic target (Otto and Sicinski, 2017). Interestingly, CDK1 activity
is rarely deregulated in cancer, though studies have shown that it contributes to
tumorigenesis (Otto and Sicinski, 2017). Indeed, CDK1 knockdown in liver was shown to
prevent NRAS-driven liver tumor formation and CDK1 inhibition prevented KRAS-driven
colorectal cancer xenograft growth in mice (Diril et al., 2012; Costa-Cabral et al., 2016).
WEE1 kinase is overexpressed in many cancers, such as melanoma and
glioblastoma. Interestingly, heterozygous deletion of WEE1 in mammary tissue
increased the incidence of mammary tumor formation, whereas homozygous deletion
did not, suggesting that complete loss of WEE1 might oppose tumor formation (Mir et al.,
2010; Vassilopoulos et al., 2015). Despite this finding, WEE1 is still considered an
oncogene and is being actively pursued as a cancer therapeutic. A promising WEE1
inhibitor, AZD1775, in currently performing well alone and in combinatorial therapies in
over twenty clinical trials, with WEE1 inhibition proving to be synthetic lethal with other
compounds, such as PARP and HDAC inhibitors, in several cancers (Rajeshkumar et
al., 2011; Karnak et al., 2014; Mueller et al., 2014).
Aurora A is frequently amplified in prostate and breast cancers and is
overexpressed in several other types of cancer (X. Wang et al., 2006; Lin-Yu Lu et al.,
2008; Staff et al., 2010b; Xu et al., 2013; Wang et al., 2014). Aurora A overexpression
inactivates the DNA damage checkpoint during G2 phase and the spindle assembly
checkpoint during mitosis, causing aneuploidy, centrosome amplification and premature
onset of cytokinesis as well as form mammary tumors in mice, underscoring its role as
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an oncogene (Dutertre, Descamps and Prigent, 2002; Marumoto et al., 2002; Meraldi,
Honda and Nigg, 2002a; S. M. a Lens, Voest and Medema, 2010). PLK1 is often
overexpressed in tumors and correlates with poor prognosis (S. M. a Lens, Voest and
Medema, 2010). The mechanism by which PLK1 contributes to tumorigenesis remains
unclear though it is speculated that it compromises the cell cycle checkpoints, resulting
in genomic instability through premature progression through the cell cycle (Osada and
Simizu, 2000; Kanaji et al., 2006). Interestingly, PLK1 loss in mice increases the
incidence of tumors, suggesting PLK1 might play a tumor suppression role in certain
contexts (L.-Y. Lu et al., 2008). Both Aurora A and PLK1 inhibitors are being pursued in
clinical trials and appear to be promising therapeutics (Otto and Sicinski, 2017).
Genomic instability in cancer and therapeutic implications
Two decades ago, Hanahan and Weinberg proposed that most cellular
characteristics that enable cells to acquire malignant capabilities were the manifestation
of six hallmarks (Hanahan and Weinberg, 2000). After a decade of new research and
insight, they expanded their model to include additional hallmarks and to highlight that
genome instability and mutation acquisition constitute enabling characteristics that
promote the acquisition of these hallmarks (Hanahan and Weinberg, 2011). Genomic
instability, which leads to increased mutability, bestows cancer cells with genetic
changes that facilitate tumor progression. More specifically, certain acquired mutations
will confer cells with a selective growth advantage, allowing their outgrowth in a tissue.
As the cell undergoes aberrant and accelerated cell cycling, it becomes more vulnerable
to DNA damage through DNA replication perturbations and failure of protective
pathways to detect and repair DNA lesions. Eventually, mutations that allow checkpoint
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bypass prevent cells from undergoing senescence and apoptosis and facilitate their
clonal outgrowth and possible dissemination.
In support of genetic instability driving tumorigenesis, many studies have
established that early tumorigenesis is associated with activation of a DNA damage
response (DDR), which protects against development into malignancy (DiTullio et al.,
2002; Bartkova et al., 2005; Karakaidos et al., 2005). Furthermore, it was shown that
oncogene expression results in DNA replication stress, which if unrepairable will trigger
oncogene-induced senescence (Bartkova et al., 2006; Di Micco et al., 2006; Fikaris et
al., 2006; Bartek, Bartkova and Lukas, 2007; Burhans and Weinberger, 2007). Finally,
models in which repair pathway proteins, such as ATR and ATM, are lost display
increased tumor incidence, suggesting their pivotal role in cancer prevention (Harper
and Elledge, 2007; Jackson and Bartek, 2009; Ciccia and Elledge, 2010; Negrini,
Gorgoulis and Halazonetis, 2010). Together, these data highlight the importance of the
DNA replication and damage checkpoints in preventing genomic instability and disease.
The pattern of mutations found in specific cancers can be utilized to subtype
them. Studies have shown that cancers that share similar genome alterations respond
similarly to certain therapies and offer comparable prognostics. Therefore, increasing our
understanding of how these patterns arise, whether it be from sites in the genome being
more sensitive to certain stresses or to loss of specific protective repair components, can
provide insight into how to treat these malignancies. Indeed, cancer cells are in a
perpetual state of replication stress, forcing them to become more reliant on DNA
replication checkpoints. Exploiting this reliance for therapeutic treatments through
synthetic lethality allows for targeted cancer cell therapies that have minimal off target
effects. Our work and that of others have shown that inhibition of the ATR-CHK1
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pathway suppresses the growth of a broad spectrum of cancers and synergistically
increases DSBs and cell death (Gilad et al., 2010a; Murga et al., 2011a; Toledo et al.,
2011; Ma et al., 2012; Prevo et al., 2012; Schoppy et al., 2012a).
In addition, by further understanding how the genome is stabilized and by
characterizing the features that render parts of the genome more sensitive to certain
stabilization pathways will enhance our comprehension of tumor pathogenesis and our
ability to develop novel and more targeted therapeutics. Using genome-wide and
proteomic techniques to probe the genome landscape and the replication dynamics
observed under conditions of replication stress in combination with compromised
genome stabilization mechanisms will improve our understanding of the key pathways
involved in driving tumor progression and inform our patient treatment courses, from
discovering exploitable synthetic lethal interactions to identifying responsive patient
cohorts.
Summary
Previous work from our laboratory has shown that fork collapse in ATR-deficient
cells is mediated through the activation of the AURKA-PLK1 pathway, suggesting that a
key part of ATR-mediated replication fork stabilization is a consequence of inhibiting
premature activation of the AURKA-PLK1 pathway (Ragland et al., 2013) (Figure 1.1).
To test this hypothesis, we created a cell-based system in which we hyperactivated the
AURKA-PLK1 pathway through kinase overexpression and co-expression of binding
partners. In Chapter 2, we report that premature activation of this pathway was
insufficient to induce fork collapse. We observed that CDK1 activation was limiting and
without its activation, the AURKA-PLK1 pathway could not engage in a self-driven
feedforward pathway to drive premature entry into mitosis, ultimately leading to fork
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collapse. However, when WEE1 kinase, a negative regulator of CDK1, was inhibited,
fork collapse occurred, suggesting that one major fork stabilizing function of ATR is to
prevent premature activation of the mitotic CDK1-AURKA-PLK1 pathway to avoid
premature entry into mitosis.
To further investigate the mechanisms essential in replication fork stabilization,
we used genome-wide techniques and proteomics to determine whether ATR maintains
fork integrity through its cell cycle checkpoint role or its local fork protection role, whether
some sites of the genome are more dependent on one role over the other for genome
stability and whether some replisome components or recruited factors play important
roles in stabilization (Figure 1.2). In Chapter 3, we show that in the context of partial
replication inhibition, WEE1 and ATR inhibition cause similar levels of fork collapse at
overlapping genomic locations and that fork collapse at these sites is dependent on
CDK1 and Aurora A kinase. Interestingly, while WEE1 inhibition is sufficient to cause
replication fork collapse in a manner similar to ATR inhibition, WEE1 inhibition further
promotes fork collapse through mechanisms distinct from ATR inhibition because WEE1
inhibition produces a distinct subset of sites compared to ATR inhibition. This could
result from WEE1 inhibition leading to a depletion nucleotide levels, ultimately causing
an additional source of replication stress. We show that the cell cycle checkpoint
function of ATR is the essential mechanism by which ATR maintains fork integrity under
conditions of replication stress.
Together, these studies provide a better understanding of the stabilization
mechanisms of DNA replication forks under conditions of replication stress as well as the
pathways driving fork collapse in checkpoint defective cells, giving us better insight on
how to leverage these findings for more effective patient therapies.
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Figure Legends
Figure 1.1. Model figure for Chapter 2: ATR stabilizes forks by preventing the premature
activation of the CDK1-AURKA-PLK1 pathway. When ATR is absent or inhibited, the
AURKA-PLK1 pathway is prematurely activated and results in premature entry into
mitosis as well as in the degradation or removal of replisome components, leading to
fork stalling and inability to restart replication.
Figure 1.2. Model figure for Chapter 3: WEE1 inhibition inhibits ATR’s cell cycle
checkpoint function while leaving its local fork protection role intact. ATR stabilizes forks
through its direct fork protection role and its cell cycle checkpoint role. WEE1 inhibition
activates the CDK cell cycle controlled pathways that ATR inhibits as part of its cell cycle
checkpoint role. However, WEE1 inhibition leaves ATR’s direct fork protection role intact.
Using WEE1 inhibition as a tool to dissect between ATR’s two fork stabilizing functions,
we showed that ATR’s cell cycle checkpoint role is essential for fork stability.
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CHAPTER 2: Premature activation of the AURKA-PLK1 pathway is insufficient to
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Summary
Genome maintenance is required to maintain cellular viability, and thus failure to
preserve genomic integrity is associated with an increased risk of cancer, accelerated
aging and a higher incidence of other diseases. To ensure genomic stability, cells have
checkpoints that control progression through the cell cycle. The S phase checkpoint is
regulated by the ATR-CHK1 pathway that stabilizes stalled replication forks and
prevents their collapse into DNA double-strand breaks (DSBs). Our laboratory has
previously shown that fork collapse in ATR-deficient cells is mediated through the
activation of the AURKA-PLK1 pathway, suggesting that a key part of ATR-mediated
replication fork stabilization is a consequence of inhibiting premature activation of the
AURKA-PLK1 pathway.
In an effort to test if premature activation of the AURKA-PLK1 pathway is
sufficient to induce fork collapse, we established a system to hyper-activate the AURKAPLK1 pathway. We are the first to show that Aurora A overexpression alone is
insufficient to activate PLK1. Indeed, co-expression of Aurora A co-activators, TPX2 and
BORA, is required for PLK1 phosphorylation. However, we found that achieving levels of
pathway activation that lead to replication fork collapse as measured by gH2AX requires
CDK1 activation. In addition, because the AURKA-PLK1 pathway is frequently
dysregulated in a multitude of cancers, we hypothesized that this aberrant activation
would increase reliance on the ATR-CHK1 pathway. Such an outcome would cause
replication forks to collapse more readily following ATR-CHK1 inhibition. We found that
Aurora A hyperactivation synergizes with ATR inhibition to increase DSB formation but
does not with CHK1 inhibition. Together our findings indicate that hyperactivation of the
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AURKA-PLK1 pathway is not sufficient to cause fork collapse but does lead to increased
reliance on ATR-mediated fork stabilization functions.
Introduction
The faithful duplication of a cell’s genome is ensured by the accuracy of the DNA
replication process and by a series of cell cycle checkpoints that coordinate cell cycle
progression with that of proper genomic replication and stability. One of these cell cycle
checkpoints is the S phase DNA replication checkpoint, which is regulated by the Ataxia
Telangiectasia and Rad3-related protein (ATR)- Checkpoint Kinase 1 (CHK1) pathway.
This pathway is activated under conditions of replication stress, defined by increased
uncoupling of the DNA helicase from the replicative polymerase, leading to the
accumulation of RPA-coated single stranded DNA. The resulting stalled fork structure is
stabilized through the recruitment of ATR, which prevents fork collapse into double
strand breaks (DSB). It has been established that replication stress is intrinsically linked
to genomic instability, but the underlying mechanisms remain unclear. Establishing these
mechanisms would provide us with a better understanding of the driving forces behind
tumorigenesis, as oncogene expression has been shown to result in replication stress,
ultimately providing us with novel therapeutic avenues to explore.
Our work and that of others have aimed to better comprehend the signaling
pathways involved in preventing fork collapse under conditions of replication stress and
how those interplay with the ATR-CHK1 checkpoint pathway. Recently, our studies have
shown that the Aurora A (AURKA)-Polo-like Kinase1 (PLK1) pathway plays an active
role in replication fork collapse following ATR inhibition. Indeed, suppression of the
AURKA-PLK1 pathway allows replication to restart after fork collapse in ATR-deficient
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cells and can partially prevent fork collapse into DSBs. These data suggest that ATR
stabilizes forks by preventing premature AURKA-PLK1 pathway activation.
The AURKA-PLK1 pathway plays several essential roles during cell division,
including regulation of mitotic entry, centrosome duplication, spindle formation,
chromosome segregation and cytokinesis (Glover et al., 1995; Richter et al., 2000;
Hirota et al., 2003a; Marumoto et al., 2003; Marumoto, Zhang and Saya, 2005). The
multitude of processes that Aurora A is involved in is tightly regulated by its association
with co-activators, which include BORA, TPX2, astrin, ajuba and HEF1, that dictate
Aurora A’s localization, activation and substrate specificity (Kufer et al., 2002b; Eyers et
al., 2003; Hirota et al., 2003a; Elena N Pugacheva and Golemis, 2005; Hutterer,
Berdnik, Wirtz-Peitz, Igman, et al., 2006; Du et al., 2008; Seki, Coppinger, Jang, et al.,
2008). Both AURKA and PLK1 are amplified in cancers, including breast, colorectal and
ovarian cancers (Takahashi et al., 2000, 2003; Weichert et al., 2004; Kitajima et al.,
2007). Therefore, a better understanding of how dysregulation of the AURKA-PLK1
pathway impacts genome stability is key to discovering new therapeutic interventions.
Although our laboratory has shown that AURKA-PLK1 signaling is required for
replication fork collapse in ATR-deficient cells, it has not been determined whether
premature activation of the AURKA-PLK1 pathway is sufficient to promote fork collapse
(Ragland et al., 2013). It is known that ATR signaling inhibits the AURKA-PLK1 pathway
in response to replication stress. Therefore, the ability of ATR inhibition to cause fork
collapse might be the result of premature AURKA-PLK1 activation. Herein, we establish
that overexpression of Aurora A or stabilized mutants of Aurora A are not sufficient to
hyperactivate the AURKA-PLK1 pathway. Aurora A overexpression must be combined
with expression of its co-activators, such as TPX2 or, preferably BORA, to achieve
activation of the pathway as determined by increased phospho-PLK1 levels. Additionally,
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we show that lack of CDK1 activity limits the activation of the AURKA-PLK1 pathway and
that when CDK1 is uninhibited through WEE1 inhibition, hyperactivation of the AURKAPLK1 pathway is partially required to induce fork collapse into DSB, as measured by
increased levels of gH2AX, and to accelerate inhibition of DNA replication restart
following replication fork stalling with aphidicolin. Both the WEE1 inhibition-induced
DSBs and inability to restart are rescued by Aurora A and PLK1 inhibition, suggesting
that despite ATR activation, hyperactivation of the CDK1-AURKA-PLK1 pathway is a key
component in promoting fork stalling and collapse into DSBs. Finally, we demonstrate
that Aurora A overexpression results in an increased reliance on ATR for fork
stabilization and is synthetic lethal with ATR inhibition, though surprisingly not with CHK1
inhibition. Altogether, our data suggests that ATR stabilizes replication forks and
prevents their collapse into DSBs in part by inhibiting the premature activation of the
CDK1-AURKA-PLK1 pathway, highlighting the importance of the ATR-CHK1 cell cycle
progression checkpoint function for genomic integrity.
Results
Establishing a cell-based system to hyperactivate the Aurora A-PLK1 pathway
Aurora A overexpression is achieved in MCF10A and 293T cells through an
inducible vector system.
To determine if hyperactivation of the Aurora A-PLK1 pathway is sufficient to
promote fork collapse, a cell-based system was established in which the AURKA-PLK1
signaling pathway could be amplified. Two human cell lines were chosen to overexpress
Aurora A: Human Embryonic Kidney 289T (HEK293T) cells for ease of plasmid
transfection, and the non-tumorigenic breast epithelial cells MCF10A, which could be
further used to study the contribution of AURKA-PLK1 pathway hyperactivation in breast
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tumorigenesis. Using retroviral transduction, Aurora A was overexpressed, but over a
period of 2-3 days, cells slowly downregulated Aurora A expression, and within a week,
reestablished endogenous levels (data not shown). This result was unanticipated
because Aurora A has been reported to be frequently amplified in a spectrum of
cancers, including breast, colorectal, and ovarian cancers and was therefore expected to
confer a survival advantage to the cells (Sen, Zhou and White, 1997; Bischoff et al.,
1998; Miyoshi et al., 2001; Gritsko et al., 2003; Vader and Lens, 2008; Staff et al.,
2010a). Because Aurora A overexpression was shown to induce aneuploidy and
genomic instability, ultimately causing malignant transformation in the absence of
checkpoints, we hypothesized that cells overexpressing Aurora A were either quickly
eliminated in culture by being selected against due to their genomic instability or had cell
intrinsic pathways that limited aberrant AURKA-PLK1 pathway amplification (Tatsuka et
al., 1998; Zhou et al., 1998; Meraldi, Honda and Nigg, 2002b; Chung et al., 2005; X.
Wang et al., 2006). To prevent cells from downregulating Aurora A expression over time
as a result of constant Aurora A expression, cell lines that inducibly overexpressed
Aurora A were created using retroviral transduction. Two MCF10A cell lines were
generated and selected for by treating with puromycin to ensure that the majority of the
cells expressed the puro-resistant Aurora A amplifying inducible construct. In both cell
lines, Aurora A expression was induced within 6 hours of tamoxifen treatment and
maximal expression was achieved at 24 hours of tamoxifen treatment (Figure 2.1).
Aurora A overexpression leads to Aurora A autophosphorylation at T288 but does
not lead to PLK activation nor is sufficient to induce DNA damage.
Induction

of

Aurora

A

expression

led

to

an

increase

in

Aurora

A

autophosphorylation at the Thr288 site, a mark suggested to reflect Aurora A activation,
indicating that the induced protein kinase is catalytically active and therefore able to
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phosphorylate its downstream target PLK1 and activate the AURKA-PLK1 pathway
(Figure 2.2A). However, despite Aurora A autophosphorylation, no increase in phosphoPLK1 levels was observed, indicating that Aurora A activation is not sufficient to
hyperactivate the AURKA-PLK1 pathway (Figure 2.2A). In addition, Aurora A
overexpression did not result in double strand break (DSB) formation, as determined by
a lack of increased levels of the DSB surrogate marker gH2AX (Figure 2.2B). To ensure
that the changes observed accurately reflected modulations in the nucleus and were not
diluted out from cytoplasmic signals, markers of AURKA-PLK1 pathway activation were
probed for in the insoluble nuclear fraction of the cell (Figure 2.2B). The chromatin
fraction similarly displayed an increase in phospho-Aurora A levels without an increase
in phopho-PLK1 levels.
Expression of a phosphomimetic mutant of Aurora A leads to Aurora A stability
and autophosphorylation.
Aurora A expression peaks during mitosis and is rapidly degraded after G2/M
phase through phosphorylation events that target the protein for degradation via the
APCCdh1-ubiquitin-proteasome pathway (Honda et al., 2000; Katayama et al., 2001;
Littlepage and Ruderman, 2002b; Littlepage et al., 2002; Taguchi et al., 2002; Horn et
al., 2007). The ubiquitin ligase APC/CCdh1 recognizes two sequences that are required
for Aurora A kinase proteolysis: the C terminus D box (destruction box), and the N
terminus A box, which includes the serine 51 site (Castro et al., 2002; Littlepage and
Ruderman, 2002b). The serine 51 site of Aurora A is phosphorylated during M phase to
stabilize Aurora A and is dephosphorylated upon mitotic exit by PP2A to control the
timing of Aurora A destruction (Walter et al., 2000; Littlepage et al., 2002; Horn et al.,
2007). To ensure that the induced Aurora A protein was not being prematurely degraded
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and prevented from binding to its co-activators, a phosphomimetic mutant at the serine
51 site was created that has previously been shown to be sufficient to stabilize the
protein (Kitajima et al., 2007). The inducible AURKAS51D-ERT2 protein was highly
expressed in MCF10A cells when treated with tamoxifen and led to elevated levels of
T288 autophosphorylation (Figure 2.3). However, expression of the phosphomimetic
mutant of Aurora A was still not sufficient to lead to increased levels of phospho-PLK1
levels or gH2AX (data not shown).
Co-expression of Aurora A with co-activators, TPX2 or BORA, results in an
increase in PLK1 activation but not increased levels of DNA damage.
Aurora A is known to require binding partners for maximal activation or for
activation at particular cellular locations as a means to tightly regulate the location and
timing of its expression (Kufer et al., 2002b; Hirota et al., 2003a; Carmena, Ruchaud and
Earnshaw, 2009; Li et al., 2015). Its most well-characterized binding partners are TPX2
and BORA, which have been shown to significantly enhance Aurora A kinase activity,
making them excellent candidates as co-activators of Aurora A in our system. Indeed,
TPX2 has been shown to both promote Aurora A autophosphorylation and to protect it
from dephosphorylation (Bayliss et al., 2003a; Eyers et al., 2003; Tsai et al., 2003b;
Eyers and Maller, 2004; Dodson and Bayliss, 2012a). We hypothesized that despite an
increase in Aurora A autophosphorylation in our system, we were not achieving PLK1
phosphorylation due to insufficient levels of Aurora A coactivators. Because MCF10A
cells are difficult to transfect, HEK293T cells that stably expressed the inducible
AURKAS51D-ERT2 construct were used. These cells were transiently transfected with
mCherry-TPX2, resulting in robust TPX2 expression (Figure 2.4). Combining Aurora A
overexpression with TPX2 expression led to a slight increase in phospho-PLK1 levels
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(Figure 2.4). However, this slight increase in AURKA-PLK1 pathway activation did not
result in an increase in gH2AX (Figure 2.5). It was unclear if the lack of DNA damage
was due to insufficient hyperactivation of the AURKA-PLK1 pathway or if hyperactivation
was achieved, but remained insufficient to cause fork collapse. As such, this question
bears further investigation.
Unlike TPX2, which acts on Aurora A to keep it activated, BORA activates the
AURKA-PLK1 pathway further downstream at the level of PLK1 activation (Hutterer,
Berdnik, Wirtz-Peitz, Igman, et al., 2006; Seki, Coppinger, Jang, et al., 2008; Parrilla et
al., 2016). In this regard, BORA is a more promising pathway activator as the hurdle
appears to be in achieving PLK1 phosphorylation. Indeed, BORA is known to interact
with PLK1 and control the accessibility of the PLK1 activation loop for phosphorylation
by Aurora A. Before BORA can bind to PLK1, it is primed through CDK1 phosphorylation
at serine 252 (Feine et al., 2014; Tavernier et al., 2015; Thomas et al., 2016). Moreover,
in order to tightly regulate AURKA-PLK1 pathway activation at the G2/M phase of the
cell cycle, BORA is degraded in early mitosis to prevent further pathway activation in
following cell cycle phases. Proteolysis of BORA is mediated through its phosphorylation
at a conserved site within the DSGxxT degron domain that promotes its interaction with
the ubiquitin ligase SCF-β-TrCP, which catalyzes its ubiquitination and marks it for
proteosomal degradation (Chan et al., 2008b; Seki, Coppinger, Du, et al., 2008). To
maximize PLK1 binding to BORA and bypass BORA degradation, the double mutant
BORAS252D/T501A was generated and transiently transfected in HEK293T cells that also
stably expressed the inducible AURKAS51D-ERT2 construct. Co-expression of the
stabilization mutant with Aurora AS51D overexpression led to an increase in phospho-
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PLK1 levels but not to an increase in levels of DNA damage (Figure 2.6 and data not
shown).
CDK1 activation allows for Aurora A-PLK1 activation and DNA damage.
Aberrant activation of the CDK1-AURKA-PLK1 pathway, which controls G2/M
cell cycle entry could result in premature entry into mitosis and chromosome
condensation followed by segregation. If DNA replication is not complete and cells
prematurely go through cell division, this would result in severe genomic instability and
cytogenetic defects. As a result, tight regulation of mitotic entry pathway activation
exists. We hypothesized that despite overexpression of stabilized components of the
AURKA-PLK1 pathway, hyperactivation of the pathway was restricted due to limitation
by a key regulator. CDK1 is a key regulator of cell cycle progression, by modulating
entry into M phase through activation of mitotic pathways (Nurse, 2000; Morgan, 2006).
To test if CDK1 activation limits AURKA-PLK1 hyperactivation, WEE1, a negative
regulator of CDK1, was inhibited to allow unrestricted CDK1 activation. Cells were
treated with a WEE1 inhibitor, AZD1775, at concentrations of 300nM and 1uM for 3
hours, which resulted in an increase in phospho-PLK1 levels (Figure 2.7). Interestingly,
WEE1 inhibition also led to an increase in gH2AX levels (Figure 2.7). These results
suggest that CDK1 activation allows for AURKA-PLK1 pathway hyperactivation, which
might be sufficient to cause fork collapse and DSB formation.
WEE1 inhibition-induced DSB formation depends on AURKA-PLK1 pathway
activation.
To test if DSB formation induced by WEE1 inhibition is a result of AURKA-PLK1
pathway hyperactivation, cells were treated with WEE1 inhibitor for 30 min, 1 hr, 2 hr
and 3 hr with or without Aurora A inhibitor. Levels of gH2AX were measured as a readout
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for DSB formation (Figure 2.8). Interestingly, despite ATR-CHK1 pathway activation as
early as 30 min, determined by increased phospho-CHK1 levels, forks still collapsed into
DSBs as early as 1 hour, determined by increased gH2AX levels at 1 hour of WEE1
inhibitor treatment (Figure 2.8). Early DSB formation depends on AURKA-PLK1 pathway
activation as gH2AX levels decreased upon Aurora A inhibitor treatment at 1 hr, 2 hr and
3 hr of WEE1 inhibitor treatment. By 3 hr of WEE1 inhibitor treatment, gH2AX levels
decreased upon Aurora A inhibition, but not to basal levels, indicating that Aurora Aindependent pathways might become activated and result in fork collapse. One
possibility could be that, as it has previously been shown, WEE1 inhibition leads to
CDK1-dependent degradation of RRM2, resulting in nucleotide shortage followed by fork
stalling and collapse into DSBs (Beck et al., 2010, 2012; Domínguez-Kelly et al., 2011;
D’Angiolella et al., 2012; Pfister et al., 2015). Indeed, RRM2 levels are stable at early
time points of WEE1 inhibition, but by 3 hr of inhibition, RRM2 levels slightly decreased,
suggesting that a shortage in nucleotide levels could contribute to WEE1 inhibitioninduced DSBs after 3 hr of WEE1 inhibition (Figure 2.9). This would further explain why
Aurora A inhibition can only partially rescue DSB formation. To further validate that
WEE1 inhibition-induced DSB formation depends on AURKA-PLK1 pathway activation,
cells were treated with WEE1 inhibitor for 30 min, 1 hr, 2 hr and 3 hr with or without
PLK1 inhibitor (Figure 2.10). As seen with Aurora A inhibitor, PLK1 inhibition led to a
decrease in gH2AX levels at early time points and to a partial decrease after 3 hr of
WEE1 inhibition (Figure 2.10). These data suggest that DSB formation induced by
WEE1 inhibition results in part from hyperactivation of the AURKA-PLK1 pathway.
WEE1 inhibition is sufficient to prevent DNA replication restart and is rescued by
AURKA-PLK1 pathway inhibition
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To study the impact of AURKA-PLK1 pathway hyperactivation on DNA
replication, we utilized the replication restart assay developed by our laboratory. This
assay allows us to study the ability of stalled forks to restart replication by monitoring the
percent of cells that were originally replicating (BrdU positive) to continue replicating
(EdU positive) after a period of inhibited replication achieved by using the replicative
polymerase inhibitor, aphidicolin (Figure 2.11a) (Ragland et al., 2013). In this assay, S
phase cells were labeled with BrdU for 30 min before treating with aphidicolin and WEE1
inhibitor for 1 hr or 3 hrs. Cells were then washed and pulsed with EdU for 1 hr. BrdUlabeled S phase cells were assayed for their ability to restart replication by monitoring
the percent of cells that were also EdU positive. At the high dose of WEE1 inhibition
(1uM), WEE1 inhibition was sufficient to prevent replication restart in 11% of cells with 1
hr treatment and in 56% of cells with 3 hr treatment (Figure 2.11b). Impressively, even at
the low 300nM dose of WEE1 inhibition, up to 25% of cells were unable to restart
replication after 3 hrs of treatment. In comparison, WEE1 inhibition prevented replication
restart 3 times faster than ATR inhibition, consistent with the fact that fork collapse
caused by ATR loss could be due to premature activation of the AURKA-PLK1 pathway
(data not shown). Indeed, ATR inhibition begins to prevent replication restart after 3 hrs
of treatment, whereas WEE1 inhibition does it as early as 1 hr of treatment.
To determine if inhibition of replication restart by WEE1 inhibition was dependent
on AURKA-PLK1 pathway activation, the restart assay described above was employed
in the absence or presence of AURKA or PLK1 inhibitors. Aurora A and PLK1 inhibition
rescued WEE1 inhibition-induced inability to restart replication, suggesting that despite
ATR activation, premature activation of the AURKA-PLK1 pathway is involved in causing
fork collapse and preventing replication restart (Figure 2.11c).

75

Aurora A overexpression is synthetic lethal with ATR inhibition but not CHK1
inhibition
Aurora A is a known oncogene amplified in many cancers. We and others have
shown that oncogene-induced replication stress coupled with ATR suppression
synergistically increases DSB formation (Gilad et al., 2010b; Murga et al., 2011b; Toledo
et al., 2011; Toledo, Murga and Fernandez-Capetillo, 2011; Schoppy et al., 2012b;
Zeman and Cimprich, 2014b). Additionally, inhibition of Aurora A-PLK1 signaling allows
stalled forks to reinitiate replication in ATR-deleted cells. Conversely, as shown above,
hyperactivation of the AURKA-PLK1 pathway through WEE1 inhibition promotes
replication fork collapse and prevents replication fork restart, suggesting that
hyperactivation of the pathway could lead to an increased reliance on ATR for fork
stabilization and become synthetic lethal with ATR-CHK1 inhibition. To test this
hypothesis, cells were transiently transfected with an AURKAS51D-ERT2 construct and
treated with tamoxifen to overexpress non-degradable Aurora A and with increasing
doses of VE-822 to inhibit ATR. Immunoblot analysis of whole cell lysates demonstrated
that ATR inhibition combined with Aurora AS51D overexpression led to synergistic
increases in gH2AX at all tested doses of ATR inhibition (Figure 2.12a).
Interestingly, when the same cells were treated with CHK1 inhibitor, only a slight
increase in gH2AX levels was seen when combined with Aurora A overexpression
(Figure 2.12b). This result could be explained by the fact that ATR has local fork
protection functions that CHK1 does not, and thus CHK1 inhibition would be expected to
retain some level of fork protection and consequently contribute to less fork collapse.
Alternatively, synergy is not observed because CHK1 inhibition on its own causes
maximal levels of gH2AX, preventing a visible synergistic increase when combined with
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Aurora A overexpression. To test this possibility, this experiment would have to be
repeated with lower doses of CHK1 inhibition. Together, these data suggest that patients
with cancers that overexpress or amplify AURKA would benefit from therapies using
ATR inhibitors.
Discussion
The results shown here are the first to establish that hyperactivation of the
AURKA-PLK1 pathway through WEE1 inhibition is sufficient to cause replication fork
collapse. This finding suggests that a crucial part of ATR-mediated replication fork
stabilization is a function of its regulation of the AURKA-PLK1 pathway.
According to the literature that demonstrated that Aurora A overexpression or
amplification alone was sufficient to transform cells, induce mitotic abnormalities and
lead to tumorigenesis (Zhou et al., 1998; Meraldi, Honda and Nigg, 2002b; Chung et al.,
2005; X. Wang et al., 2006; X. X. Wang et al., 2006; Zhang et al., 2008), as well as the
literature showing that Aurora A activated the PLK1 pathway (Macůrek et al., 2008; Seki,
Coppinger, Du, et al., 2008; Bruinsma et al., 2014b), we hypothesized that Aurora A
overexpression alone would be sufficient to activate the AURKA-PLK1 pathway. We
were surprised to find that Aurora A overexpression alone, including that of nondegradable Aurora A protein constructs, was not sufficient to lead to PLK1 activation.
Autophosphorylation at the T288 site in Aurora A was observed, which was previously
thought to be a mark of activation. However, it was later shown that non-phosphorylated
Aurora A in complex with TPX2 at the mitotic spindle is catalytically active, suggesting
that the autophosphorylation state of Aurora A might be an inaccurate surrogate for its
activity (Dodson and Bayliss, 2012a). This finding could be context dependent, but
based on our lack of PLK1 phosphorylation when Aurora A was overexpressed, it seems
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that the increase in phosphorylation at T288 did not correlate with activation of the
AURKA-PLK1 pathway. In addition, in the studies in which Aurora A overexpression
alone was sufficient to transform cells, it is possible that either the cell lines were
naturally altered to allow for AURKA-PLK1 pathway activation, such as through p53
mutation or activation of CDK1, or that the cell transformation was a consequence of the
dysregulation of PLK1-independent functions of Aurora A. Our data are the first to show
that Aurora A overexpression alone is not sufficient to activate the AURKA-PLK1
pathway. Instead, as was previously shown, activation of the AURKA-PLK1 pathway
occurred through co-expression of Aurora A co-activators TPX2 and BORA. However,
the level of activation required to result in fork collapse within hours could not be
achieved without activating CDK1, which we believe to be the limiting switch for maximal
pathway activation, as it occurs normally at the transition into M phase.
Model for fork collapse induced by AURKA-PLK1 pathway activation
Previously our laboratory has shown that when ATR is depleted, the CDK1AURKA-PLK1 pathway is activated, resulting in fork collapse (Ragland et al., 2013). We
now show that activation of the CDK1-AURKA-PLK1 pathway using WEE1 inhibition is
required for fork collapse, despite having an intact ATR-CHK1 checkpoint pathway. The
mechanism by which activation of the CDK1-AURKA-PLK1 pathway can promote fork
collapse is unknown, but we propose that it is mediated through the premature loss of
replisome components. Replisome disengagement is a process that naturally occurs at
sites of replication termination and during M phase transition and is regulated by the
CDK1-AURKA-PLK1 pathway (Freire et al., 2006; Mailand et al., 2006; Mamely et al.,
2006; Peschiaroli et al., 2006); therefore, aberrant activation of this mitotic fork
termination pathway in S phase could lead to the premature removal of replication
factors, resulting in fork collapse (Liu, Song and Liu, 2010; Dheekollu et al., 2011).
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Indeed, PLK1 has previously been implicated in DNA replication checkpoint termination
and entry into mitosis through its βTrCP ubiquitin ligase-mediated degradation of
Claspin, a known replisome component (Yoo et al., 2004; Mailand et al., 2006;
Peschiaroli et al., 2006). In addition, PLK1 was shown to control βTrCP-dependent
degradation of FANCM, a replisome component, during mitosis (Kee et al., 2009).
Finally, our laboratory observed a general loss of replisome components under
conditions of ATR inhibition and AURKA-PLK1 activation (Ragland et al., 2013).
Altogether, these data suggest that premature activation of the CDK1-AURKA-PLK1
pathway could lead to premature degradation of the replisome, causing fork collapse.
Fork collapse from loss of replisome factors could be a consequence of exposing the
bare DNA structure of a fork that occurs once DNA-bound protein complexes are
removed, rendering it accessible to endonucleases that can cleave it into a DSB. In
addition to stripping the fork, activation of AURKA-PLK1 pathway could be promoting the
activation of fork-targeting nucleases. Indeed, studies have shown that PLK1 is required
for the activation of MUS81-EME1 and its association with SLX4 and that these
nucleases are responsible for fork cleavage to promote replication fork restart
(Domínguez-Kelly et al., 2011; Muñoz-Galván et al., 2012; Kai J. Neelsen et al., 2013;
Szakal and Branzei, 2013a; Wyatt et al., 2013b; Alessandra Pepe and West, 2014b).
Future studies that determine which proteins are present at the fork under conditions of
CDK1-AURKA-PLK1 pathway hyperactivation using iPOND2 could elucidate how CDK1AURKA-PLK1 pathway hyperactivation results in fork collapse, which could occur either
by loss of replisome proteins or the recruitment of endonucleases at the fork (Sirbu et
al., 2011; Sirbu, Couch and Cortez, 2012; Rivard et al., unpublished).
Clinical relevance
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Aurora A is a known oncogene amplified in many cancers. Our findings indicate
that Aurora A overexpression results in an increased reliance on ATR and is synthetic
lethal with ATR inhibition. With ATR inhibitors already being assessed as cancer
therapeutics in clinical trials, our data has promising potential for novel opportunities that
can be rapidly implemented for the treatment of cancers with amplified AURKA, such as
breast and ovarian cancers (Charrier et al., 2011; Ma, Janetka and Piwnica-Worms,
2011; Reaper et al., 2011; Toledo, Murga and Fernandez-Capetillo, 2011). Furthermore,
oncogenes such as KRASG12D and MYC, expression of which are synthetic lethal with
ATR inhibition (Gilad et al., 2010b; Murga et al., 2011b; Toledo et al., 2011; Schoppy et
al., 2012b; Zeman and Cimprich, 2014b), promote AURKA expression and activity
(Macůrek et al., 2008; Maris, 2009; Otto et al., 2009; den Hollander et al., 2010;
Brockmann et al., 2013; Yang et al., 2013; Hilton and Shapiro, 2014; Dauch et al., 2016;
Richards et al., 2016), therefore, broadening the number and types of cancers that can
be targeted with ATR inhibitor therapies.
Future Directions
The model we propose is the first to suggest that ATR suppression leads to fork
collapse as a result of aberrant activation of the CDK1-AURKA-PLK1 pathway. In light of
our recent genome-wide work characterizing replication perturbed regions under
conditions of ATR suppression combined with replication stress (Shastri, Tsai et al.
2017), it would be interesting to determine if these same sites are affected by
hyperactivation of the CDK1-AURKA-PLK1 pathway. If so, these finding would suggest
that the key role of ATR fork stabilization stems from its inhibition of premature cell cycle
progression through activation of the CDK1-AURKA-PLK1 pathway. In addition, further
studies designed to query the proteins and pathways involved in ATR-mediated
replication fork stabilization through iPOND2 will clarify our fundamental understanding
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of replication fork dynamics when the checkpoint response is activated. This will provide
insight into how such findings can be utilized for cancer therapies.

Material and Methods
Cell Culture
MCF10A cells were cultured in Dulbecco's modified Eagle's medium-F12 (1:1) with 5%
horse serum, insulin (10 μg/ml), hydrocortisone (0.5 μg/ml), and epidermal growth factor
(20 ng/ml), cholera toxin (100ng/ml), streptomycin (100 µg/mL) and penicillin (100
units/ml). HEK293T cells were cultured in a 3% O2 and 6% CO2 atmosphere at 37°C in
Dulbecco modified Eagle’s medium (Mediatech, MT10-013-CV) supplemented with 10%
fetal bovine serum (Gemini BioProducts, 100-106), 2mM L-glutamine (Mediatech, 25005-CI), and 100 µg/mL streptomycin, 100 units/ml penicillin (Invitrogen, 15140-122).
MCF10A cells stably overexpressing Aurora A were generated by infecting them with
retrovirus expressing the AurAWT-ERT2 or AurAS51D-ERT2 inducible fusion protein from
the pBabe puro human Aurora A plasmid (Addgene plasmid #8510) followed by
puromycin selection at 20ug/mL of puromycin for 3 days. For additional protein
expression, cells were transiently transfected using Lipofectamine 3000 (Invitrogen) as
per manufacturer’s directions and using 24ug of indicated plasmid. Plasmid used were
pmCherry-TPX2 (Addgene, plasmid 31227) and MGC Human BORA cDNA accession #
BC025367 (Thermo Fisher MHS6278-202830791). All plasmid site directed mutagenesis
was performed using the Agilent QuikChange Site Directed Mutagenesis Kit according
the manufacturer’s directions.
Human retrovirus creation and infection
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To generate retroviruses, HEK293T cells were transfected using the calcium phosphate
method with the retroviral expression vector and a ψ2 vector. Control and pBabe puro
human Aurora A retroviral vectors were purchased from Addgene (#1764 and #8510,
respectively). For retroviral infection, MCF10A cells were infected with virus and
polybrene (8ug/ml) using spin infection at 18C for 1 hr at 2500 rpm and left to incubate
with the virus for 24hrs. The cell culture medium was then replaced and 24 hours after
recovery in fresh medium, cells were selected with increasing concentration of
puromycin.
Aurora A expression induction
Aurora A expression was induced in AurA-ERT2 infected cell lines by the addition of 0.5
uM 4-hydroxytamoxifen (4-OHT; EMD) to the culture medium for 6 or 24 hours. The 4OHT was added at the time of plating and washed out 6 or 24 hours later. Cells were
then cultured for an additional 24 hours after 4-OHT washout to afford effective
expression of the Aurora A protein, at which time cells were collected for analysis. If cells
were transfected with a plasmid for TPX2 or BORA co-expression, cells were transfected
24 hours after plating and 4-OHT was added 24 hours after that. Expression levels and
DNA damage induction were assessed 24 hours after 4-OHT addition.
Chemical inhibitors
All chemical inhibitors were added to the cell medium 24 hours after 4-OHT addition for
a treatment duration of 6 hours. The inhibitor used for ATR inhibition is VE-822
(SelleckChem) and for CHK1 inhibition is PF477736 (Tocris) at the doses indicated in
the figure legends.
Chromatin extraction and fractionation
Extractions were performed as described by Mendez and Stillman (2000). Briefly, cells
were collected by trypsin treatment and lysed in buffer A (10 mM HEPES at pH 7.9,
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0.1% Triton-X, 10 mM KCl, 1.5 mM MgCl2, 0.34 M sucrose, 10% glycerol and protease
inhibitors (Roche)) for 5 min at 4°C. Lysates were centrifuged at 1300g for 5 min. The
resulting supernatant was mixed 1:1 with 2X Laemmli sample buffer and collected as the
cytoplasmic fraction. Pellets were washed in buffer A once and incubated in buffer B (3
mM EDTA, 0.2mM EGTA, protease inhibitors (Roche)) for 30 min at 4°C. The samples
were centrifuged at 1700g for 5 min, and the resulting supernatant was collected and
mixed 1:1 with 2X Laemmli sample buffer to generate the nuclear-soluble fraction.
Pellets from this extraction were washed in buffer B twice prior to a final centrifugation at
1700g for 5 min. The pellets were resuspended in buffer A and mixed 1:1 with 2X
Laemmli sample buffer to generate the nuclear-insoluble fraction. All samples were
boiled for 5 min prior to protein quantification as described below.
Western immunoblotting
Cells were resuspended in PBS and lysed with Laemmli sample buffer (final
concentrations of 10% glycerol, 2% SDS, 60 mM Tris, pH 6.8) and boiled for 5 minutes.
Protein concentration was determined by bicinchoninic acid protein assay (Thermo
Fisher Scientific, 23225). The total protein quantities were normalized, loaded on a 420% gradient SDS-polyacrylamide gel (Bio-Rad, 456-1093) and separated by
electrophoresis. Proteins were then transferred to 0.45 μM polyvinylidene fluoride
(PVDF) membranes, blocked in 5% milk in TBST for 1 hour at RT, bound overnight to
primary antibodies in 0.25% milk in TBST at 4°C, washed with TBST, bound to HRPconjugated secondary antibody in 0.25% milk in TBST for 1 hour at RT, washed with
TBST and then detected with chemiluminescence (Thermo Scientific, 34080). Blots were
detected for phospho-PLK1 (Cell Signaling Technology, 5472S), phospho-S345 Chk1
(Cell Signaling Technology, 2348s), phospho-S139 H2AX (Millipore, 05-636), RFP
antibody for TPX2 detection (Abcam, ab62341), Aurora A (Abcam, Ab13824), phospho83

T288 Aurora A (Cell signaling, 3079), MCM3 (Bethyl Laboratories, A300-124A), GAPDH
(US Biological, G8140-01), BORA (Abcam, ab182149).
Figure Legends
Figure 2.1. MCF10A cells can inducibly overexpress AURKA. MCF10A cells expressing
the parent vector (Empty) or AURKAS51D-ERT2 as is (0) or selected with 1.5ug/mL of
puromycin (1.5) were either not treated (-) or treated (+) with 4-OHT for 6 or 24hrs and
detected for total AURKA levels by western blot. *endogenous AURKA, ** AURKAS51DERT2. Two different AURKAS51D-ERT2 overexpressing cell lines are used.
Figure 2.2. Aurora A overexpression is not sufficient to activate PLK1 or induce DSBs.
(A) Whole cell lysates of MCF10A cells expressing the parent vector (Empty) or
AURKAS51D-ERT2 either not treated (-) or treated (+) with 4-OHT for 24hrs and in the
presence or absence of 25uM anacardic acid for 4hrs (as an AURKA coactivator/binding partner surrogate) were analyzed by Western blot. Levels of phoshoPLK1, phospho-AURKA, total AURKA and gH2AX were assessed. (B) Western blot of
chromatin fractions of samples described in A assessed for levels of phosho-PLK1,
phospho-AURKA and total MCM3 levels. *endogenous AURKA, ** AURKAS51D-ERT2.
Two different AURKAS51D-ERT2 overexpressing cell lines are used.
Figure 2.3. Induction and activation of chromatin-bound AURKAS51D-ERT2 after 4-OHT
treatment. MCF10A cells (10A), expressing the parent vector (Empty) or AURKAS51DERT2 were either not treated (-) or treated (+) with 4-OHT for 24hrs and detected for
chromatin-bound total and activated (phos-T288) AURKA by western blot. MCM3 is a
loading control. *endogenous AURKA, ** AURKAS51D-ERT2. Two different AURKAS51DERT2 overexpressing cell lines are used.
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Figure 2.4. Transient overexpression of TPX2 in stably expressing AURKAS51D-ERT2
cells slightly increased phospho-PLK1 levels. HEK293T cells stably expressing the
parent vector (Empty) or AURKAS51D-ERT2 (AURKA), with and without co-expression of
TPX2, were left untreated (-) or treated (+) with 4-OHT for 24hrs to induce the proper
folding and localization of AURKAS51D-ERT2. Samples were assessed for AURKA,
phospho-PLK1 and TPX2 levels (with RFP antibody which recognizes the mCherry tag
of TPX2) by western blot. *endogenous AURKA; ** AURKAS51D-ERT2.
Figure 2.5. Transient co-overexpression of AURKAS51D-ERT2 with TPX2 increases
levels of AURKA autophosphorylation. HEK293T cells transfected with the parent vector
(Empty) or AURKAS51D-ERT2 (AURKA), with and without co-expression of TPX2, were
left untreated (-) or treated (+) with 4-OHT for 24hrs to induce the proper folding and
localization

of

AURKAS51D-ERT2.

Samples

were

assessed

for

total

and

autophosphorylated AURKA and phospho-PLK1 by western blot. GAPDH is a loading
control. *endogenous AURKA; ** AURKAS51D-ERT2. Two different AURKAS51D-ERT2
overexpressing cell lines are used (#1 and #2).
Figure 2.6. Transient co-overexpression of AURKAS51D-ERT2 with BORA activates
PLK1. HEK293T cells transfected with the parent vector (Empty) or AURKAS51D-ERT2
(AURKA),

with

and

without

co-expression

of

BORA

mutants

(BORAT501A

or

BORAT501A/S252D) were treated with 4-OHT for 24hrs to induce the proper folding and
localization of AURKAS51D-ERT2. Chromatin fractions of samples were assessed for
induced AURKA expression and levels of phospho-PLK1 and MCM3 by western blot.
Figure 2.7. WEE1 inhibition is sufficient to activate the AURKA-PLK1 pathway and
induce fork collapse. Western blot detection gH2AX, p-PLK1 and pCHK1 of whole cell
lysates from cells treated with indicated dose of WEE1 inhibitor (WEE1i).
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Figure 2.8. WEE1 inhibition-induced DSB formation depends on AURKA. Western blot
detection gH2AX, p-PLK1, pCHK1 and GAPDH of whole cell lysates from cells treated
with 3uM WEE1 inhibitor (WEE1i) for indicated times in the presence or absence of
10uM AURKA inhibitor (AURKAi).
Figure 2.9. WEE1 inhibition-induced DSB formation does not affect RRM2 levels.
Western blot detection RRM2, MCM3 and GAPDH of whole cell lysates from cells
treated with 3uM WEE1 inhibitor (WEE1INH) for indicated times in the presence or
absence of 10uM AURKA inhibitor (AURKAINH).
Figure 2.10. WEE1 inhibition-induced DSB formation depends on PLK1. Western blot
detection gH2AX, p-PLK1, pCHK1, total CHK1 and GAPDH of whole cell lysates from
cells treated with 3uM WEE1 inhibitor (WEE1i) for indicated times in the presence or
absence of 10uM PLK1 inhibitor (PLK1i).
Figure 2.11. AURKA and PLK1 inhibition prevent WEE1 inhibition-induced replication
fork collapse. (A) Dual-labeling method to measure replication restart by flow cytometry.
Pulse cells with BrdU to label S-phase cells before the fork collapse-inducing treatment
of 5 uM aphidicolin (Aph) and subsequently monitor these cells for replication restart
following treatment wash out by EdU pulse labeling. Flow cytometry plots display the
level of EdU labeling (X-axis) of BrdU-positive cells across the cell cycle (PI stain on the
Y-axis) (B) Representative examples of replication restart assessed by flow cytometry
following WEE1 inhibitor (WEE1i) and 5uM Aphidicolin (Aph) treatment. Cells were
pulsed with BrdU for 30 min, which was then washed off, followed by 1 or 3 hours of
treatment with 5uM Aphidicolin and WEE1 inhibitor at indicated doses. Inhibitors were
washed off and cells were pulsed with EdU for 1 hour. Flow cytometry plots of EdU
labeling (X-axis) of BrdU-positive cells of indicated conditions are shown. (C)
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Representative examples of replication restart assessed by flow cytometry following
treatment of AURKA and PLK1 small molecule inhibitors (AURKAi and PLK1i,
respectively). Cells were pulsed with BrdU for 30 min, which was then washed off,
followed by 3 hours of treatment with WEE1 inhibitor and 5uM Aphidicolin with or without
either AURKA or PLK1 inhibitors. Inhibitors were washed off and cells were pulsed with
EdU for 1 hour. Flow cytometry plots of EdU labeling (X-axis) of BrdU-positive cells of
indicated conditions are shown.
Figure 2.12. Overexpression of stabilized AURKA increases reliance on ATR but not on
CHK1 for genome stability. (A) Cells transfected with the parent vector (“V”) or
AURKAS51D-ERT2-expresssing vector (“A”) were treated with 4-OHT for 3 hours to
activate AURKAS51D-ERT2 and then treated with indicated dose of VE-821 ATR inhibitor
(“VE”) for an additional 6 hours. Western blot detection of gH2AX, AURKA and GAPDH
is shown. (B) Cells transfected with the parent vector (“V”) or AURKAS51D-ERT2expresssing vector (“A”) were treated with 4-OHT for 3 hours to activate AURKAS51DERT2 and then treated with indicated dose of CHK1 inhibitor (PF477736) for an
additional 6 hours. Western blot detection of phos-H2AX, AURKA and GAPDH is shown.
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Summary
Checkpoints control cell cycle progression in the event of DNA damage or
incomplete DNA replication. The DNA replication checkpoint is regulated by the ATRCHK1 pathway, which also stabilizes stalled replication forks and prevents their collapse
into DNA double-strand breaks. Two distinct models have been proposed to explain how
ATR stabilizes stalled forks: 1) through local modulation of fork remodelers, and 2)
through inhibition of CDK-dependent pathways, which prevents cell cycle progression.
To test if CDK1-activation is sufficient to promote fork collapse, we inhibited WEE1,
which short-circuits the cell cycle checkpoint function of ATR without inhibiting its forkproximal activity. Using flow cytometry based fork collapse assays and genome-wide
detection of RPA accumulation (RPA-ChIP Seq), we find that WEE1 and ATR inhibition
cause similar levels of fork collapse at overlapping genomic locations in a CDK1depdendent manner under conditions of partial replication inhibition (low dose
aphidicolin). Notably, treatment with WEE1 inhibitor (WEE1i) alone was also sufficient to
cause replication fork collapse, and did so more rapidly and to a higher degree than
ATRi alone. Interestingly, clear differences in site specificity were observed when WEE1i
was combined with ATRi, suggesting that particular sites in the genome may be slightly
more dependent on the local functions of ATR than others. Thus, cell cycle checkpoint
abrogation by WEE1i is sufficient to cause replication fork collapse in a manner similar to
ATRi; however, site-specific roles for ATR remain.
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Introduction:
Genome maintenance is essential for cell viability and disease prevention. To
ensure genomic stability, cells have checkpoints that regulate cell cycle progression
(Kastan and Bartek, 2004b). The intra-S phase DNA replication checkpoint is regulated
by the ataxia telangiectasia and Rad3-related protein (ATR) pathway, which is activated
by slowing or stalling of replication fork progression, generally referred to as replication
stress (Zou and Elledge, 2003; Karlene A. Cimprich and Cortez, 2008). Replication
stress can result in the accumulation of single-stranded DNA (ssDNA) through
uncoupling of the DNA polymerase from the MCM2-7 helicase (Byun et al., 2005; Zeman
and Cimprich, 2014a). The resulting ssDNA is then coated by replication protein A
(RPA), a ssDNA binding protein that recruits the ATR-ATRIP complex to stabilize
uncoupled forks and prevent their collapse into double-stranded breaks (DSBs) (Cortez
et al., 2001; Zou and Elledge, 2003).
Previous studies have proposed that ATR stabilizes stalled forks either through
regulation of cell cycle-dependent pathways that ultimately inhibit cell cycle progression
and origin firing or through local modulation of fork remodelers (Costanzo et al., 2003; E.
J. Brown and Baltimore, 2003; Couch et al., 2013b; Yazinski and Zou, 2016). ATR’s cell
cycle checkpoint function is primarily mediated through phosphorylation of its effector
protein, CHK1 (Liu et al., 2000; Zhao and Piwnica-Worms, 2001). Once activated, CHK1
phosphorylates CDC25A, marking it for proteasomal degradation, thereby preventing
origin firing (Mailand et al., 2000; Feijoo et al., 2001; Zhao and Piwnica-Worms, 2001;
Chen, Ryan and Piwnica-Worms, 2003b). CHK1 also phosphorylates CDC25C, causing
it to bind to the 14-3-3 protein complex and sequestering it from CDK1, thereby inhibiting
cell cycle progression (Peng et al., 1997; Sanchez et al., 1997; Liu et al., 2000; Zhao
and Piwnica-Worms, 2001). Additionally, CHK1 phosphorylates WEE1, a cell cycle
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checkpoint kinase that blocks entry into mitosis and negatively regulates origin firing
through inhibitory phosphorylation of CDK1 and CDK2, respectively (O’Connell et al.,
1997; Lee, Kumagai and Dunphy, 2001; Katsuno et al., 2009; Kumar and Huberman,
2009; Sørensen and Syljuåsen, 2012). ATR has also been shown to protect forks from
endonuclease complexes, such as SLX4-SLX1 or MUS81-EME1 that can cleave
unprotected forks into DSBs, by inhibiting premature activation of CDK-dependent
pathways (Castor et al., 2013; Garner et al., 2013; Ragland et al., 2013; Szakal and
Branzei, 2013b; Wyatt et al., 2013a, 2017; Alessandra Pepe and West, 2014a; Sarbajna,
Davies and West, 2014).
ATR locally stabilizes forks by directly regulating fork remodelers, such as
SMARCAL1, which has been shown to play a role in fork protection (Couch et al.,
2013b), and Polh, which is involved in post-replicative repair (Göhler et al., 2011).
Additionally, ATR has many other fork-bound substrates that promote replication fork
stability, though the mechanisms by which this occurs are still poorly understood
(Karlene A Cimprich and Cortez, 2008; Saldivar, Cortez and Cimprich, 2017). While
much progress has been made in delineating how ATR maintains fork stability, it
remains unclear which of ATR’s fork-stabilizing functions is essential for fork integrity.
Whether ATR maintains fork integrity through its cell cycle checkpoint role or its local
fork protection role, and whether some sites of the genome are more dependent upon
one role over the other for genome stability remains to be shown.
To separate these two ATR functions, WEE1 inhibition (WEE1i) was used to bypass
ATR’s cell cycle checkpoint activity without affecting ATR’s local replication fork
functions. Wee1 inhibition permitted us to test if CDK activation was sufficient to promote
replication fork collapse in a manner that emulates ATR inhibition. By comparing the
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effects of WEE1i to those observed by ATR inhibition (ATRi), ATR’s cell cycle
checkpoint function could be distinguished from its local fork protection role.
Herein we show that in the context of partial replication inhibition (low dose
aphidicolin), WEE1i and ATRi cause similar levels of fork collapse at overlapping
genomic locations. Fork collapse at these sites was dependent on CDK1 and Aurora A
kinase (AURKA), consistent with our previous study (Ragland et al., 2013). In the
absence of direct DNA polymerase inhibition, WEE1i was sufficient to cause replication
fork collapse and did so more rapidly and to a higher degree than ATRi alone.
Consistent with this observation, we found that WEE1i depleted ribonucleotide reductase
(RRM2) levels to a greater extent than ATRi, leading to nucleotide insufficiency and,
ultimately, to fork collapse. Surprisingly, while WEE1i was sufficient to cause fork
collapse at many genomic loci that overlap with sites identified from ATRi and partial
polymerase inhibition, WEE1i also produced a distinct subset of fork collapse sites not
observed from ATRi, either in the presence or absence of partial DNA polymerase
inhibition. In summary, while WEE1i is sufficient to cause replication fork collapse in a
manner similar to ATRi, WEE1i further promotes fork collapse through mechanisms
distinct from ATRi. Future studies will examine these genomic sites for features that
render them vulnerable to fork collapse under these conditions. Our studies suggest that
the cell cycle checkpoint function of ATR is essential to maintain fork integrity under
conditions of low replication stress.
Results:
WEE1 and ATR inhibition results in similar levels of DNA damage under
conditions of replication stress
Previous studies have proposed that ATR stabilizes stalled replication forks
through both its cell cycle checkpoint function and its local role at the fork (Paulsen and
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Cimprich, 2007; Couch et al., 2013b; Zeman and Cimprich, 2014a). Our laboratory has
previously shown that fork collapse under conditions of ATR loss is mediated through
activation of the CDK1 signaling pathway (Ragland et al., 2013). This suggests that
ATR’s role in regulating cell cycle progression to prevent premature activation of mitotic
signaling pathways is important in fork stability. Thus, we hypothesized that ATR
stabilizes stalled forks primarily through its cell cycle checkpoint role. By comparing
WEE1 inhibition, which inhibits ATR’s cell cycle checkpoint function while retaining its
local fork protection function, to ATR inhibition, we can define which of ATR’s functions
are essential to stabilize stalled forks (Figure 3.1).
IC50 concentrations of the WEE1 and ATR inhibitors were initially determined by
looking at levels of phospho-PLK1 and phospho-CHK1 by immunoblot as readouts for
WEE1 and ATR inhibitor efficiency, respectively (Supplemental Figure 3.1). In the
passage-immortalized murine embryonic fibroblasts (MEFs) cell line, which is used in all
experiment thereafter, the inhibitor IC50 for WEE1 and ATR was found to be 1 µM and
0.26 µM, respectively. To ensure efficient substrate inhibition 3x the IC50 was chosen
resulting in a 3 µM and 1 µM dose used for WEE1 and ATR inhibitors, respectively.
To examine the fork stabilizing effects of the separate ATR functions, MEF cells
were treated with either 3 µM of WEE1 inhibitor (WEE1i) or 1 µM of ATR inhibitor (ATRi)
for 1, 2 and 4 hours (Figure 3.2). The treated cells were then assayed by flow cytometry
for presence of gH2AX, a surrogate marker for DSB formation. Interestingly, WEE1
inhibition led to significantly higher levels of gH2AX compared to ATR inhibition. Because
WEE1 inhibition displayed an increased capacity to cause replication fork collapse,
additional inhibitor doses were examined that result in similar amounts of DNA damage
as measured by levels of gH2AX assayed by flow cytometry. As expected, 500 nM of
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WEE1i and 5 uM ATRi resulted in equivalent levels of gH2AX at 1, 2 and 4 hours of
treatment (Figure 3.2).
WEE1 inhibition and to a lesser extent ATR inhibition induce RRM2 depletion
WEE1 inhibition has previously been shown to cause replication stress and
subsequent fork collapse through RRM2 degradation-induced nucleotide depletion
(D’Angiolella et al., 2012; Pfister et al., 2015). This finding led us to hypothesize that
WEE1i-induced gH2AX levels were higher compared to ATR inhibition at 3x the IC50 as a
result of WEE1 inhibition being sufficient to cause replication stress on its own. To test if
replication stress caused by WEE1 is mediated by nucleotide depletion resulting from
RRM2 degradation, cells were treated with low or high doses of WEE1 and ATR
inhibitors for 4 hours and examined for RRM2 protein levels (Figure 3.3). RRM2 levels
were reduced in a dose-dependent manner with WEE1 inhibition and were almost
undetectable at 3 µM WEE1i. Interestingly, ATR inhibition also led to a slight decrease in
RRM2 levels in a dose-dependent manner, but to a lesser extent than WEE1 inhibition
(Figure 3.3). The most prominent difference in RRM2 levels between WEE1 and ATR
inhibition was seen at the 3x IC doses, which are also the doses at which we observe a
large difference in gH2AX levels. However, RRM2 levels were comparable between 500
nM WEE1i and 5 µM ATRi, suggesting that the increase in gH2AX levels seen with
WEE1i could result from replication stress induced by nucleotide depletion.
To test if replication stress contributed in part to the difference seen in gH2AX
levels between 3 µM WEE1i and 1 µM ATRi, we treated MEF cells with the WEE1i or
ATRi and with a low dose (0.2μM) of aphidicolin (APH), a DNA polymerase alpha and
delta inhibitor, which is known to induce low levels of replication stress through fork
slowing (Figure 3.4). When assayed by flow cytometry for levels of gH2AX, we found that
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WEE1 and ATR inhibition following partial replication stress led to similar levels of
gH2AX accumulation at all time points, again suggesting that the original difference
observed between WEE1 and ATR inhibition was due to an inherent ability of WEE1i to
cause replication stress. More importantly, these data together suggest that the cell
cycle checkpoint role of ATR is important in preventing gH2AX accumulation in the
absence or presence of replication stress. As expected, when the experiment was
repeated with high dose of APH (5 µM), which induces complete fork stalling, WEE1i
and ATRi under high replication stress conditions resulted in similar levels of gH2AX,
indicating the requirement for the cell cycle checkpoint role of ATR in fork stabilization
(Supplemental Figure 3.2).
WEE1 inhibition activates CDK1 and ATR signaling
To determine what other molecular signaling differences differentiate WEE1i and
ATRi treatments, MEF cells were treated with the inhibitors for 4 hours and probed by
immunoblot for substrates of the WEE1 and ATR signaling pathways (Figure 3.3). As
expected, WEE1 inhibition significantly reduced phospho-CDK1 levels and increased
phospho-PLK1 levels, both of which were unaffected by ATR inhibition at the 4 hour time
point. Additionally, WEE1 inhibition alone significantly increased phospho-CHK1 levels,
a readout of replication stress and ATR activation, again supporting that WEE1 inhibition
alone can induce replication stress. Because WEE1 inhibition alone is sufficient to
induce replication stress, it increases dependence on the ATR signaling pathway to
prevent fork collapse. However, under conditions of WEE1 inhibition, the cell cycle
checkpoint function of ATR is inhibited, leaving forks vulnerable to collapse, ultimately
leading to DNA damage. Such an outcome is not observed with ATR inhibition alone
since no exogenous replication stress is triggering a dependence on the ATR signaling
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pathway for fork stability, and thus, inhibition of the pathway does not lead to DNA
damage. In contrast, aphidicolin-induced replication stress creates a dependence on the
ATR signaling pathway such that both WEE1 and ATR inhibition results in similar levels
of DNA damage.
WEE1 inhibition leads to greater DNA replication inhibition compared to ATR
inhibition
Notably, phospho-CHK1 levels increase within 15 minutes of WEE1i treatment
but RRM2 levels do not decrease until 3 hours of treatment, suggesting that there might
be another mechanism by which WEE1 inhibition leads to fork collapse, such as
premature mitotic entry. To test if WEE1 and ATR inhibition led to similar replication
dynamic profiles, we looked at replication fork collapse and restart as a functional output
of fork stability. MEF cells were treated with WEE1 or ATR inhibitors for 4 hours, after
which the drugs were washed out (Figure 3.5a). The cells were then allowed to reinitiate
DNA replication in the presence of EdU. Using flow cytometric analysis, we determined
the percentage of S phase cells that did not incorporate EdU as a readout for cells that
were unable to restart replication. As expected, 3 µM WEE1i prevented DNA replication
restart more robustly than 1 µM ATRi, again suggesting that WEE1i alone is sufficient to
cause replication stress that results in replication defects. Consistent with the DNA
damage data, 5 µM ATRi and 0.5 µM WEE1i displayed similar levels of DNA replication
restart capabilities.
The experiment was repeated in the context of low replication stress (0.2 µM
APH) to determine if WEE1i-induced replication stress was responsible for the increased
replication defects seen in WEE1i-treated cells (Figure 3.5b). Interestingly, unlike what
was observed with DNA damage, additional replication stress did not equalize the
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amount of replication defects observed between 3 µM WEE1i and 1 µM ATRi, possibly
indicating that different mechanisms might regulate the DNA damage and replication
restart phenotypes observed with WEE1i treatment.
To test if high levels of replication stress could equalize the replication fork restart
defects seen between WEE1i- and ATRi- treated cells, the replication restart assay was
performed with 5 µM APH for 1, 2 and 4 hours of treatment (Figure 3.5c). At 2 hours of
treatment, 3 µM WEE1i still had significantly increased inability to restart replication
compared to 1 µM ATRi but by 4 hours of treatment, that difference disappeared. This
data suggests that by 4 hours, the elevated levels of replication stress induced by 5 µM
APH can level the WEE1i-induced replication stress in the ATRi-treated samples to
cause similar replication defects. Because a replication defect difference is still seen by
2 hours of treatment between 1 µM ATRi and 3 µM WEE1i, at which point RRM2 levels
are not decreased, it is possible that a nucleotide depletion independent mechanism is
responsible for the replication defects observed. Together, these data establish that the
cell cycle checkpoint role of ATR is important in preventing DNA replication inhibition in
the absence or presence of replication stress.
CDK1 inhibition decreases gH2AX accumulation and rescues DNA replication
inhibition induced by WEE1 and ATR inhibition
Based on the differences observed between 1 µM ATRi and 3 µM WEE1i in
inducing DNA damage and causing replication restart defects in the context of
replication stress, we hypothesized (1) that cell cycle checkpoint loss was inducing DNA
damage and replication defects and (2) that different mechanisms might be regulating
these phenotypes. To gain insight into the molecular mechanism by which WEE1 and
ATR inhibition lead to DNA damage and DNA synthesis inhibition, we used a dual
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CDK1/2 inhibitor, RO-3306, at a dose that inhibits CDK1 without affecting CDK2. We
tested the effects of CDK1 inhibition on the ability of MEFs to restart replication under
conditions of WEE1 or ATR inhibition with or without 0.2μM APH treatment. Cells were
subsequently assayed for DNA damage and for the ability to restart DNA replication
(Figures 3.6). CDK1 inhibition was able to rescue DNA damage across both
concentrations of WEE1 and ATR inhibitors with no or low dose of APH (Figure 3.6a). In
addition, CDK1 inhibition also allowed cells to restart replication under all conditions
(Figure 3.6b). These data suggest that ATR stabilizes forks through inhibition of the
CDK1 pathway, which acts as a major signaling axis in its cell cycle checkpoint function.
To further tease apart the signaling pathways through which WEE1 inhibition
leads to DNA damage and replication restart defects, we next inhibited AURKA, which
functions downstream of CDK1 (Hirota et al., 2003b; Van Horn et al., 2010). Using the
same assays described above, MEF cells were examined for their ability to restart
replication and to cause DNA damage after treatment with an AURKA inhibitor (Figure
3.6a). Under conditions of high-dose APH, AURKA inhibition rescued DNA replication
that was unable to restart under WEE1 or ATR inhibition (Figure 3.6b). These data
suggest that the inability of DNA replication to restart from WEE1 and ATR inhibition is
mediated through the CDK1-AURKA signaling axis. Under conditions of no or low
replication stress, we found that AURKA inhibition only rescues the block in DNA
replication induced by WEE1 inhibition and, though not significant, displays some level
of rescued DNA replication under conditions of ATR inhibition as well. Surprisingly, while
AURKA inhibition rescued DNA replication restart, it did not rescue the DNA damage
induced by WEE1 or ATR inhibition. This finding suggests that DSB formation occurs
upstream of AURKA inhibition or through a different pathway downstream of CDK1, such
as through regulation of endonuclease fork cleavage or through nucleotide metabolism.
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In support of nucleotide levels having an effect on the DSB formation observed
with WEE1i and ATRi, we observed that CDK1 inhibition restores RRM2 levels in WEE1i
treated cells under conditions of no or low replication stress (Figure 3.6c,d). AURKAi
was not sufficient to restore RRM2 levels (Figure 3.6c,d). These data suggest that in the
context of WEE1i, CDK1i may be rescuing DSB formation through restoration of
nucleotide levels. Because RRM2 levels do not appear to be altered with ATRi, we
believe that other DSB forming mechanisms are at play downstream of CDK1, such as
endonuclease fork cleavage.
RPA ChIP-Seq peaks are similar in WEE1 and ATR inhibited cells under conditions
of replication stress
Our data indicates that ATR and WEE1 inhibition result in similar levels of DNA
damage in a population of cells under conditions of replication stress. To better
understand if those conditions led to similar fork stalling signatures at the genomic level,
we performed RPA-chromatin immunoprecipitation (RPA-ChIP) on MEF cells following
treatment with WEE1 or ATR inhibition in combination with low-dose APH to retrieve
genomic sites that accumulate RPA. As mentioned previously, RPA is a protein that
binds ssDNA that accumulates at stalled forks and at resected DSB ends resulting from
collapsed forks; therefore, RPA accumulation defines regions sensitive to fork stalling or
collapse.
RPA ChIP was performed on MEF cells treated for 18 hours with low-dose APH
(0.2μM) and 1 µM ATRi or 0.5 µM WEE1i (ATRi+APH and WEE1i+APH, respectively).
The lower doses of inhibitors were used for therapeutic relevance as WEE1 and ATR
inhibitors are synthetic lethal when combined in mouse models (Simpkin lab data) and
these doses displayed similar levels of DNA damage under conditions of replication
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stress. A higher dose of APH was not used in these experiments since complete
replication inhibition would result in site mapping of the replication fork location at the
time of treatment and not of sites that are specifically sensitive to WEE1 or ATR
inhibition. RPA ChIP was similarly performed on DMSO-only treated (UT) cells as a
treatment control, and pre-ChIP input DNA from each condition was isolated for
normalization. We used next generation sequencing (NGS) to perform genome-wide
mapping of the RPA ChIP retrievals (Figure 3.7a).
After normalizing the retrievals to the input to create ratio tracks, we identified
sites that had statistically significant read enrichments (>4-fold over input, p-value <10-3)
in both of two biological replicates (Figure 3.7a). These sites were then compared to
similarly normalized and evaluated DMSO-treated controls. In total, 216 and 913 sites of
significant RPA enrichment were identified in ATRi+APH and WEE1i+APH conditions,
respectively, that were not observed in the DMSO-treated controls (Figure 3.7b). As
expected, the majority (135 of 144) of loci identified in the ATRi+APH-treated cells were
found in the WEE1i+APH-treated cells. The 9 sites that appear to be unique to the
ATRi+APH condition displayed some level of read accumulation in the WEE1i+APH
coverage tracks and so would have to be confirmed as unique by qRT-PCR, which is
more quantitative. If these sites are unique, this would indicate that a few sites in the
genome depend on the local roles of ATR to maintain fork stability. Notably,
WEE1i+APH treatment resulted in an additional 711 sites of significant RPA
accumulation, consistent with previous observations that WEE1 inhibition alone may be
sufficient to cause replication stress.
Intrigued by the differences in DNA damage and synthesis we observed between
ATR and WEE1 inhibition alone (Figures 3.2 and 3.5a), we performed RPA ChIP-Seq to
better understand the genomic profile of perturbed loci under these two conditions in the
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absence of exogenous replication stress. The ChIP retrievals were derived as described
previously in cells treated with low doses of WEE1 or ATR inhibitor without APH
treatment. We identified 88 and 269 sites of significant RPA enrichment in ATRi and
WEE1i conditions, respectively (Figure 3.7b). As expected, WEE1 inhibition alone
produced 3 times more sites than ATR inhibition alone, with 196 of 269 of those sites
unique to WEE1 inhibition and 17 of 88 being unique to ATRi inhibition. 67 of 88 of the
ATRi sites overlapped with WEE1i sites. Future studies are required to confirm that
unique sites are truly unique and if so to determine what features might distinguish them
and make them more dependent on the local functions of ATR.
Since WEE1 inhibition alone causes replication stress, we found it appropriate to
compare RPA ChIP retrievals from cells treated with WEE1i to those treated with
ATRi+APH. Interestingly, only 112 out of 216 ATRi+APH sites were found to overlap in
both conditions, with 151 sites unique to WEE1i and 95 unique to ATRi+APH (Figure
3.7b). This suggests that the replication stress induced by WEE1i affects sites differently
than the stress induced by aphidicolin (see Discussion).
Finally, to assess if ATRi+APH treatment compared to WEE1i+APH treatment
lead to similar genomic loci but with different signal intensity, we used Spearman
correlation to measure how similar the signal intensity of each overlapping sites between
both conditions was (Figure 3.7c; Sup. Fig. 3.3). We found that the majority of peaks
shared relative similarity in peak intensity between all pairwise condition observed with a
few exceptions highlighted in red (Figure 3.7c; Sup. Fig. 3.3).
Together these data indicate that under conditions of replication stress, the cell
cycle checkpoint function of ATR is crucial in maintaining replication fork stability at
specific loci. In the absence of replication stress, though the majority of sites depend on
the cell cycle checkpoint function of ATR for fork stabilization, 25% of sites found in
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ATRi-treated cells might depend more on the local functions of ATR for fork stabilization.
Notably, the majority of shared sites between conditions showed similar peak signal
intensities, suggesting that genome-wide effects observed at a cellular level, like the
level of DNA damage, are likely a result of the number of sites affected by the treatment
rather than by an increased frequency (amplified ChIP signal intensity) of specific sites
breaking.
Discussion:
The results presented here are the first to demonstrate that in the absence and
presence of partial polymerase inhibition the cell cycle checkpoint function of ATR is
almost entirely responsible for maintaining fork stability. Additionally, we show that fork
collapse is dependent on CDK1, which we hypothesize to be mediated through its
control of endonucleases and/or of nucleotide levels, and that replication fork restart is
dependent in part on the CDK1-AURKA pathway. Notably, WEE1i alone is sufficient to
cause replication fork collapse, and did so more rapidly and to a higher degree than
ATRi alone, which we propose results from WEE1i-induced RRM2 depletion.
Furthermore, unique site specificity was observed when WEE1i was combined with
ATRi, suggesting that particular sites in the genome are more dependent on the local
functions of ATR than others. Our characterization of fork collapse induced by WEE1i
and ATRi provides novel insight into how these inhibitors are affecting specific loci
genome-wide and how these genomic fork collapse signatures could be used for the
treatment of cancer.
Without replication stress, WEE1 inhibition significantly increased phospho-CHK1
and gH2AX levels compared to ATR inhibition alone and led to fork collapse at a set of
unique loci compared to ATR inhibition with or without APH. Our findings are consistent
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with previous reports in the literature that have shown that WEE1 depletion leads to a
marked increase in gH2AX and phosphorylation of ATR targets such as CHK1 and RPA
(Beck et al., 2010, 2012; Domínguez-Kelly et al., 2011; Heijink et al., 2015). Together,
these data suggest that WEE1 inhibition alone is sufficient to induce replication stress,
causing a dependence on the ATR signaling pathway to prevent fork collapse. Under
conditions of WEE1 inhibition, the cell cycle checkpoint function of ATR is inhibited
leaving forks vulnerable to collapse, suggesting that ATR’s local fork protection role is
not sufficient to prevent fork collapse. DNA damage is not observed with ATR inhibition
alone because no replication stress is triggering a dependence for the ATR signaling
pathway for fork stability so inhibition of the pathway has no effect. In contrast, when
cells are treated with aphidicolin, aphidicolin-induced replication stress creates a
dependence on the ATR signaling pathway such that both WEE1 and ATR inhibition
result in similar levels of DNA damage. The fact that WEE1 inhibition alone is sufficient
to cause replication stress could explain the difference we observe in DNA damage
levels when ATR and WEE1 are inhibited under conditions of no replication stress,
which is not observed under conditions of replication stress.
Our genome-wide studies confirm the DNA damage data collected at a cell
population level. Indeed, ATRi with or without replication stress affected the same
genomic loci as those observed with WEE1i, highlighting the importance of the cell cycle
checkpoint pathway in preventing replication fork collapse at all genomic loci observed.
WEE1i alone gave rise to 25 unique loci. Interestingly, these sites were not affected
when replication stress was added though it remains unclear why. As expected, with
aphidicolin addition, 319 sites become uniquely sensitive to fork collapse and finally
when both ATR and WEE1 are inhibited combined with aphidicolin a new set of 322
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sites appear to specifically be sensitive to that combination treatment, suggesting that
the local functions of ATR might somehow help stabilize these sites under conditions of
replication stress when WEE1 is inhibited. The mechanism by which this occurs is
unclear and insight might be gained from studying features that characterize these sites.
Additionally, future studies would include determining which of these sites collapse into
DSBs by analyzing our genome-wide data generated using the Breaks Identified by TdTLabeling (BrITL) technique, which detects DSBs as well as by understanding which of
these sets of loci can be rescued by CDK1 or AURKA inhibition.
Studies have shown that WEE1 inhibition is lethal to cancer cells through dNTP
starvation-induced replication stress because WEE1 inhibition promotes ubiquitinmediated proteolysis of RRM2 (D’Angiolella et al., 2012; Pfister et al., 2015). Consistent
with this, we observe a drastic decrease in RRM2 levels in our system under WEE1
inhibition, which we do not see with ATR inhibition. In addition, RRM2 loss is dose
dependent, with increased RRM2 loss seen at the higher WEE1i dose, lending insight
into the differences we saw in levels of DNA damage between ATR and WEE inhibition
at the high doses. In support of RRM2 depletion contributing to WEE1i-induced fork
collapse in our system is our finding that a CDK1 inhibitor, RO-3306, which rescues fork
collapse, also restores RRM2 levels. However, some studies have reported that though
nucleotide shortage induces WEE1i-induced DNA damage, it is not the only contributor
(Beck et al., 2012). Future studies, such as overexpression of non-degradable RRM2
mutants under WEE1i, are needed to investigate the extent to which RRM2 depletion
contributes to WEE1i-induced replication stress in our system.
Notably, the most surprising finding in the genome-wide study was that only 54%
of ATRi+Aph sites overlapped with WEE1i sites. This suggests that the replication stress
induced by aphidicolin and WEE1 inhibition affect sites differently. Hydroxyurea (HU)
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induces replication stress through nucleotide depletion, similarly to WEE1 inhibition.
Interestingly, HU is known to deplete nucleotide pools unevenly, preferentially depleting
dATP and dGTP (Collins, Oates and Collins, 1987). Based on these findings, it would
be expected for HU, and in a similar manner WEE1 inhibition, to stall forks preferentially
at sites that are enriched in adenine and guanine. Conversely, aphidicolin is a
polymerase inhibitor and so would be expected to stall forks either more stochastically or
in genomic loci where polymerases naturally have difficulty replicating DNA due to
sequence-specific structure formations. It would be interesting to see if the sites unique
to WEE1i are enriched in As and Gs and if the ones unique to ATRi+Aph are enriched in
hard-to-replicate sequences.
Interestingly, only CDK1 inhibition, but not AURKA inhibition, rescues gH2AX
induction by WEE1i and ATRi, yet both CDK1 and AURKA inhibition can rescue DNA
replication inhibition that results from ATRi and WEE1i. Studies from our laboratory have
previously shown that the CDK1-AURKA-PLK1 pathway is important in replication restart
under conditions of ATR depletion and replication stress but that PLK1 inhibition was not
sufficient to prevent DSB formation (Ragland et al., 2013). Our data is in agreement with
these findings but it still remains unclear why AURKAi is insufficient to prevent gH2AX
accumulation. One possible model is that CDK1 activation recruits and activates the
SLX4-endonuclease complex, which is known to cleave replication forks into DSBs
(Froget et al., 2007; Forment et al., 2011; Gallo-Fernández et al., 2012; Muñoz-Galván
et al., 2012; Szakal and Branzei, 2013b; Gritenaite et al., 2014). SLX4 has been
implicated in mediating replication fork collapse in partnership with the MUS81-EME1
complex (Fekairi et al., 2009; Muñoz et al., 2009; Wyatt et al., 2013a, 2017). In support
of this model, previous reports have shown that WEE1i leads to MUS81-EME1
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recruitment at forks and that MUS81 and EME1 knockdown as well as CDK1 inhibition
can reverse DSB formation triggered by WEE1 depletion (Domínguez-Kelly et al., 2011;
Beck et al., 2012; Kai J Neelsen et al., 2013; Pfister et al., 2015). If endonuclease
recruitment to the stalled fork is upstream of AURKA it would explain why CDK1
inhibition, but not AURKA inhibition, can prevent DSB formation.
Our work and that of others support a model of ATR-mediated fork stabilization
that highlights the requirement for the cell cycle checkpoint function of ATR. Indeed, we
propose that ATR’s cell cycle checkpoint function is essential to maintain fork integrity
under conditions of low replication stress through inhibition of premature CDK1
activation. Without ATR-mediated CDK1 regulation, forks will stall as a result of
nucleotide deficiency through RRM2 degradation and collapse into DSBs through SLX4MUS81-EME1 endonucleolytic fork cleavage. In addition, our data suggests that WEE1i
is inducing replication stress through means other than cell cycle checkpoint bypass,
making it an interesting cancer therapeutic candidate.
Of significance, ATR and WEE1 inhibitors are currently being used in clinical
trials and are being proposed as a combinatorial therapy for a multitude of cancers. Our
findings contribute to improving our understanding of how WEE1 inhibitors mediate
toxicity, whether combination with ATR inhibitor is beneficial, and if novel synthetic lethal
interactions can be utilized to increase treatment efficacy.
Material and Methods
Cell culture
MEF 4-3 Bcl-xL cells were generated by transducing retrovirus expressing the Bcl-xL
protein from the pMIG Bcl-XL plasmid (Addgene plasmid #8790) into MEF 4-3 cells.
Cells were cultured in a 3% O2 and 6% CO2 atmosphere at 37°C in Dulbecco modified
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Eagle’s medium (Mediatech, MT10-013-CV) supplemented with 10% fetal bovine serum
(Gemini BioProducts, 100-106), 2mM L-glutamine (Mediatech, 25-005-CI), and 100
µg/mL streptomycin, 100 units/ml penicillin (Invitrogen, 15140-122).
Inhibitor treatment
All chemical inhibitors were added to the cell culture medium at the same time. The
following chemical compounds were used: DMSO (Sigma, D2650), 1 or 5 µM ATR-45
(Charrier et al., 2011) for ATR inhibition, 0.5 or 3 µM MK-1775 (Selleckchem, Cat No.
S1525) for WEE1 inhibition, 0.2 or 5 µM aphidicolin (Calbiochem, CAS 38966-21-1) for
polymerase inhibition, 40 µM RO-3306 (Selleckchem, Cat No. S7747) for CDK1
inhibition, or 10 µM Aurora A Inhibitor I (Selleckchem, Cat No. S1451) for Aurora A
inhibition. Treatment duration is indicated in figure legends.
DNA damage assay by flow cytometry
After inhibitor treatment, cells were collected by trypsin treatment and fixed in 70% EtOH
overnight. Cells were stained with FITC-conjugated phospho-S139 H2AX antibody
(Millipore, 16-202A) for 2 h, followed by staining with PI solution (50 µg/ml PI, 0.1%
Triton X-100, 50 µg/ml RNase, and 5 mM EDTA in PBS) for 1 h. Cells were analyzed by
flow cytometry using a FACScalibur (BD) and imaged and quantified using FlowJo (Tree
Star) software.
DNA synthesis assay by flow cytometry
After cells were treated with indicated inhibitors for indicated times, chemical compounds
were removed by washing 3x with PBS, 1x with medium at 37°C, and 3x with PBS. Cells
were then incubated in 50 μM EdU for 1 h to label newly synthesizing DNA. Cells were
collected for flow cytometric analysis by trypsin treatment and fixed in 70% EtOH
overnight. EdU incorporation was detected using the Alexa Fluor-647 kit for flow
cytometry per the manufacturer's instructions (Invitrogen, C10634). DNA content was
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determined by staining cells with PI solution for 1 h. Cells were analyzed by flow
cytometry using a FACS Calibur (BD) and imaged and quantified using FlowJo (Tree
Star) software.
Immunoblotting
Cells were resuspended in PBS and lysed with Laemmli sample buffer (final
concentrations of 10% glycerol, 2% SDS, 60 mM Tris, pH 6.8) and boiled for 5 minutes.
Protein concentration was determined by bicinchoninic acid protein assay (Thermo
Fisher Scientific, 23225). The total protein quantities were normalized, loaded on a 420% gradient SDS-polyacrylamide gel (Bio-Rad, 456-1093) and separated by
electrophoresis. Proteins were then transferred to 0.45 μM polyvinylidene fluoride
(PVDF) membranes, blocked in 5% milk in TBST for 1 hour at RT, bound overnight to
primary antibodies in 0.25% milk in TBST at 4°C, washed with TBST, bound to HRPconjugated secondary antibody in 0.25% milk in TBST for 1 hour at RT, washed with
TBST and then detected with chemiluminescence (Thermo Scientific, 34080). Blots were
detected for phospho-PLK1 (Cell Signaling Technology, 5472S), phospho-S345 Chk1
(Cell Signaling Technology, 2348s), phospho-S139 H2AX (Millipore, 05-636), total Chk1
(Santa Cruz Biotechnology, sc-8408), phospho-S33 RPA32 (Bethyl Laboratories, A300246A), GAPDH (US Biological, G8140-01), tubulin (Cell Signaling, cs-3873T), phosphoY14/15 CDK1 (Santa Cruz, sc-7989), RRM2 (Santa Cruz, sc-10846).
RPA ChIP-Seq
Chromatin ImmunoPrecipitation (ChIP) assays for RPA were performed from 15 million
MEF Bcl-xL cells per experiment. Cells were crosslinked with 1% formaldehyde (Sigma,
F1635-25ML) for 10 minutes at room temperature with gentle rocking and the reaction
was quenched by glycine addition at a final concentration of 0.125 M for 10 minutes.
The cell pellet was washed in 10 ml PBS and subsequently re-suspended in 1 ml cold
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PBS. The cells were then lysed in lysis buffer (50 mM HEPES pH 7.9, 140 mM NaCl, 1
mM EDTA, 10% glycerol, 0.5% NPZ40, 0.25% Triton X-100) for 10 minutes on ice. Cell
nuclei were recovered by centrifugation at 1,500 rpm for 5 minutes at 4°C and washed
twice with washing buffer (10 mM Tris-Cl pH 8.1, 200 mM NaCl, 1 mM EDTA pH 8.0, 0.5
mM EGTA pH 8.0). The nuclei were rinsed without disturbing the pellet in 1 ml of
shearing buffer (0.1% SDS, 1 mM EDTA, 10 mM Tris pH 7.6) and after centrifugation
were re-suspended in 1 ml of shearing buffer. Chromatin was fragmented by sonication
at 4°C using a Covaris S220 (5% Duty Factor, 140 PIP, 200 cycles per burst) according
to manufacturer’s instructions resulting in an average fragment size of 200-2000bp. The
samples were centrifuged at 14,000 rpm for 20 minutes at 4°C to remove insoluble
cellular debris. The supernatant was transferred to a new tube and 10X RIPA buffer
(0.1% SDS, 1 mM EDTA, 10 mM Tris pH 7.6, 11% Triton X-100, 1.1% Na-DOC) was
added to a final 1X concentration.
Protein A Dynabeads (Invitrogen, 10002D) were antibody bound at 4°C overnight with
rotation to either 20 µg IgG (Sigma, I8765) for pre-clear beads or to 20 µg anti-RPA32
antibody (Millipore, NA19L) for IP beads in a solution comprised of 1 ml PBS, 10 µl 100
mg/ml BSA, 10 µg bridging antibody. Once antibody-bound, the beads were washed
twice with PBS. The samples were then “pre-cleared” by incubating with IgG-bound
Protein A-coated Dynabeads for 4 hours at 4°C with rotation. Once pre-cleared, 1/10th of
the sheared chromatin was frozen for use as an input control. The remaining pre-cleared
chromatin was added to RPA32-bound Dynabeads, and incubated overnight at 4°C with
rotation. The next day, the beads were washed for 10 minutes with rotation at 4°C as
follows: 2x with 1 ml of RIPA buffer, 2x with 1 ml of RIPA buffer + 0.3 M NaCl, 2x with 1
ml of LiCl buffer (0.25 M LiCl, 0.5% NP-40, 0.5% NaDOC, store at 4˚C), 1x with 1 ml of
TE (pH 8.0) + 0.2 % Triton X-100, 1x with 1 ml of TE (pH 8.0). The DNA was then eluted
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in 100 µl of TE buffer containing 0.6% SDS and 1 mg/ml Protease K, and reversecrosslinked at 65˚C overnight. The sonicated input control was reverse-crosslinked
similarly. The DNA in all samples was extracted using phenol-chloroform and
resuspended in TE buffer for ChIP-qPCR analysis or NGS library preparation.
ChIP-Seq Library preparation
500-1000ng of total ChIP DNA was used for library construction using the NEBNext DNA
library Kit for Illumina (NEB, E6000S). Sequencing was performed using the Illumina
HiSeq 2500 and 100bp single-end reads were obtained.
Sequence Alignment, Peak calling and Visualization
Sequence Alignment and Peak calling were performed as described in Tsai and Shastri
et al, 2017. Sequenced reads were trimmed using trimmomatic (Bolger et al., 2014) to
remove adapter sequences and then checked for quality control using fastqc (Leggett et
al., 2013). Trimmed reads were aligned to Mus musculus mm10 genome using STAR
Aligner with a maximum of 3 mismatches allowed (Dobin et al., 2013). Multi-mapping
was allowed for reads that mapped to up to 100 different genomic locations and reads
were de-duplicated to increase the complexity of the read population. Alignment-specific
quality-control metrics were used, such as strand-cross-correlation (Landt et al., 2012),
finger-plots (Ramírez et al., 2016) to gauge mutual back/level of enrichment across
samples, Pearson and Spearman correlations of genomic and enriched regions across
samples (≥0.6), principal component analysis (PCA) for clustering assessment, and a
non-arbitrary estimate of signal over the input tracks (Liang and Keles, 2012). Blacklisted regions in the mm10 genome were filtered out prior to peak-calling.
For enrichment analysis, an irreproducibility rate (IDR) analysis (Landt et al., 2012) from
the ENCODE project with MACS2 peak-calling program (Zhang et al., 2008) was
performed on biological replicates and inputs for each experimental condition to give the
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final peak list per condition. The IDR thresholds were >0.05 for self-consistency and
comparison of biological replicates, and >0.005 for pooled-consistency analysis. Peaks
were then filtered for those with p-value <10-3 and with above 4-fold enrichment over
input. Regions within 2 kb of one another were merged and peaks that intersected with
the peaks called in the DMSO-control RPA ChIP-Seq condition were removed.
Replicates and statistical tests
Unless otherwise noted, all data represented in figures represent three to five
independent experiments. Microsoft Excel was used for all statistical analysis. Error bars
represent the standard error of the mean, and P-values were calculated using the
Student's unpaired, 2-tailed t-test. P ≤ 0.05 was considered significant.
Figure Legends
Figure 3.1. Model figure: WEE1 inhibition inhibits ATR’s cell cycle checkpoint function
while leaving its local fork protection role intact. ATR stabilizes forks through its direct
fork protection role and its cell cycle checkpoint role. WEE1 inhibition activates the CDK
cell cycle controlled pathways that ATR inhibits as part of its cell cycle checkpoint role.
However, WEE1 inhibition leaves ATR’s direct fork protection role intact. Using WEE1
inhibition as a tool to dissect between ATR’s two fork stabilizing functions, we showed
that ATR’s cell cycle checkpoint role is essential for fork stability.
Figure 3.2. WEE1 inhibition leads to greater accumulation of DNA damage compared to
ATR inhibition. First panel shows representative examples of cell cycle flow cytometric
detection of gH2AX in cells treated with DMSO, 1 µM WEE1 inhibitor or 3 µM ATR
inhibitor for 4 hours. gH2AX (y-axis) as a readout of DNA damage was immunodetected
in asynchronous cells, co-stained for DNA content by PI (x-axis), and visualized by flow
cytometry. Percentage of gH2AX-positive cells is indicated for each condition above the
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gate. Second panel shows quantification of the % of gH2AX positive cells normalized to
the number of cells to account for cell cycle population changes. Data were collected
from minimum 3 independent experiments. Error bars represent SEM and p values were
calculated by paired 2-tailed Student's t test.
Figure 3.3. WEE1 inhibition activates CDK1 and ATR signaling and leads to RRM2
depletion. WEE1 and ATR inhibitors induce signaling changes in ATR, CDK and RRM2
signaling pathways. Western blot detection of the indicated proteins in whole cell lysates
of cells treated with or without Aphidicolin and ATR or WEE1 inhibitors for 4 h.
Figure 3.4. WEE1 and ATR inhibition results in similar levels of DNA damage under
conditions of replication stress. Top panel consists of representative examples of cell
cycle flow cytometric detection of gH2AX in cells treated with 0.2 µM Aphidicolin and
DMSO, 3 µM WEE1 inhibitor or 1 µM ATR inhibitor for 4 hours. gH2AX (y-axis) as a
readout of DNA damage was immunodetected in asynchronous cells, co-stained for
DNA content by PI (x-axis), and visualized by flow cytometry. Percentage of gH2AXpositive cells is indicated for each condition above the gate. Bottom panel consists of the
quantification of the % of gH2AX positive cells normalized to the number of cells to
account for cell cycle population changes. Data were collected from minimum 3
independent experiments. Error bars represent SEM and p values were calculated by
paired 2-tailed Student's t test.
Figure 3.5. WEE1 inhibition prevents DNA replication to a greater extent than ATR
inhibition. (A) Top panel consists of representative examples of cell cycle flow cytometric
detection of EdU in cells treated with DMSO, 0.5 µM or 3 µM WEE1 inhibitor or 1 µM or
5 µM ATR inhibitor for 4 hours, washed and then pulsed with EdU for 1 hr. EdU (y-axis)
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as a readout of DNA synthesis was immunodetected in asynchronous cells, co-stained
for DNA content by PI (x-axis), and visualized by flow cytometry. Percentage of EdUpositive and EdU-negative cells is indicated for each condition above and to the left of
the gates, respectively. Second panel show the quantification of the % of S phase DNA
content cells that are EdU negative. Data were collected from 3 independent
experiments. Error bars represent SEM and p values were calculated by paired 2-tailed
Student's t test. (B) First panel shows representative examples of cell cycle flow
cytometric detection of EdU in cells treated with 0.2 µM Aphidicolin and DMSO, 0.5 µM
WEE1 inhibitor or 1 µM ATR inhibitor for 4 hours, washed and then pulsed with EdU for
1 hr. EdU (y-axis) as a readout of DNA synthesis was immunodetected in asynchronous
cells, co-stained for DNA content by PI (x-axis), and visualized by flow cytometry.
Percentage of EdU-positive and EdU-negative cells is indicated for each condition above
and to the left of the gates, respectively. Second panel shows quantification of the % of
S phase DNA content cells that are EdU negative. Data were collected from 3
independent experiments. Error bars represent SEM and p values were calculated by
paired 2-tailed Student's t test. (C) First panel shows representative examples of cell
cycle flow cytometric detection of EdU in cells treated with 5 µM Aphidicolin and DMSO,
0.5 µM WEE1 inhibitor or 1 µM ATR inhibitor for 4 hours, washed and then pulsed with
EdU for 1 hr. EdU (y-axis) as a readout of DNA synthesis was immunodetected in
asynchronous cells, co-stained for DNA content by PI (x-axis), and visualized by flow
cytometry. Percentage of EdU-positive and EdU-negative cells is indicated for each
condition above and to the left of the gates, respectively. Second panel shows
quantification of the % of S phase DNA content cells that are EdU negative. Data were
collected from 3 independent experiments. Error bars represent SEM and p values were
calculated by paired 2-tailed Student's t test.
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Figure 3.6 CDK1 inhibition decreases gH2AX accumulation and rescues DNA replication
inhibition induced by WEE1 and ATR inhibition. (A) CDK inhibition but not AURKA
inhibition rescues WEE1 and ATR induced gH2AX. Quantification of the % of gH2AX
positive cells normalized to the number of cells to account for cell cycle population
changes. Data were collected from 3 independent experiments. Error bars represent
SEM and p values were calculated by paired 2-tailed Student's t test. P < 0.05 *; P <
0.01 **; P < 0.001***; compared to vehicle control. (B) CDK and AURKA inhibition
rescues WEE1 and ATR induced inhibition of DNA replication. Quantification of the % of
S phase DNA content cells that are EdU negative. Data were collected from 3
independent experiments. Error bars represent SEM and p values were calculated by
paired 2-tailed Student's t test. P < 0.05 *; P < 0.01 **; P < 0.001***; compared to Vehicle
control. (C) CDK inhibition but not AURA inhibition can rescue signaling changes
induced by WEE1 and ATR inhibition. Western blot detection of the indicated proteins in
whole cell lysates of cells treated with ATR or WEE1 inhibitors and either CDK1 (RO3306) or AURKA inhibitors for 4 h. (D) CDK inhibition but not AURA inhibition can rescue
signaling changes induced by WEE1 and ATR inhibition under conditions of low
replication stress. Western blot detection of the indicated proteins in whole cell lysates of
cells treated with Aphidicolin and ATR or WEE1 inhibitors and either CDK1 (RO-3306) or
AURKA inhibitors for 4 h.
Figure 3.7. RPA ChIP-Seq peaks overlap between WEE1- and ATR-inhibited cells with
or without aphidicolin. (A) RPA ChIP-Seq ratio tracks of indicated condition over its input
using 500 bp bin windows at indicated peak chromosomal location. The rows display the
ratio tracks (RPA-ChIP/Input) for the conditions as follows: 1. WEE1i, 2. ATRi, 3.
WEE1i+Aph, 4. ATRi+Aph, 5. DMSO-treated control (UT) (B) Venn diagram displaying
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overlap of peaks identified from each indicated condition (C) Spearman correlation plots
of peak signal intensity for overlapping sites between indicated conditions where W:
WEE1i, WAp: WEE1i+Aph, A: ATRi, ApA: ATRi+Aph. Red dots indicate top and bottom
5% outliers.
Supplemental Figure 3.1. Determining the IC50 for WEE1 and ATR inhibitor in MEF
cells. Western blot detection of the indicated proteins in whole cell lysates of cells
treated with indicated doses of WEE1 inhibitor (A) or ATR inhibitor with 0.2uM
Aphidicolin (B) for 4 h.
Supplemental Figure 3.2. WEE1 and ATR inhibition results in similar levels of DNA
damage under conditions of replication stress. Top panel consists of representative
examples of cell cycle flow cytometric detection of gH2AX in cells treated with 5 µM
Aphidicolin and DMSO, 0.5 µM WEE1 inhibitor or 1 µM ATR inhibitor for 4 hours. gH2AX
(y-axis) as a readout of DNA damage was immunodetected in asynchronous cells, costained for DNA content by PI (x-axis), and visualized by flow cytometry. Percentage of
gH2AX-positive cells is indicated for each condition above the gate. Bottom panel
consists of the quantification of the % of gH2AX positive cells normalized to the number
of cells to account for cell cycle population changes. Data were collected from minimum
3 independent experiments. Error bars represent SEM and p values were calculated by
paired 2-tailed Student's t test.
Supplemental Figure 3.3. RPA ChIP-Seq peaks have similar signal intensity between
WEE1- and ATR-inhibited cells with or without aphidicolin. Spearman correlation plots
on linear scale of peak signal intensity for overlapping sites between indicated conditions
where W: WEE1i, WAp: WEE1i+Aph, A: ATRi, ApA: ATRi+Aph. Red dots indicate top
and bottom 5% outliers.
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The role of the Aurora A-PLK1 pathway in replication fork collapse
The impact played by the dysregulation of the Aurora A-PLK1 pathway in
tumorigenesis has been clearly established because of the important functions it plays in
the G2-M transition as well as in mitosis in preparation for cell division, such as in
centrosome maturation, bipolar spindle assembly and chromosomal segregation
(Asteriti, De Mattia and Guarguaglini, 2015). However, the role that the Aurora A-PLK1
pathway plays in genomic stability and particularly in regulating the DNA damage
response still remains unclear. Amplification and overexpression of Aurora A promotes
tumorigenesis (Bischoff et al., 1998; Zhou et al., 1998; Meraldi, Honda and Nigg, 2002a;
X. Wang et al., 2006). Therefore, increasing our understanding of the mechanisms by
which Aurora A-induced tumorigenesis occurs will promote the development of novel
and more efficient therapeutic cancer treatments (S. M. A. Lens, Voest and Medema,
2010; Otto and Sicinski, 2017). In addition, this knowledge will assist clinician in
identifying patient populations that benefit from combinatorial treatments that take
advantage of dependencies established in an Aurora A amplified tumor by capitalizing
on synthetic lethal interactions.
Recent studies have shown that Aurora A overexpression or amplification
abrogates the G2-M checkpoint in response to DNA damage (Marumoto et al., 2002;
Cazales et al., 2005; Krystyniak et al., 2006). Aurora A overexpression postpones cyclin
B degradation and phosphorylates CDC25B, which prevents its sequestration by 14-3-3,
thereby promoting CDK1 nuclear localization and activation, stimulating mitotic entry
(Qin et al., 2009). Conversely, Aurora A inhibition delays reentry of cells into mitosis
(Marumoto et al., 2002; Gorgun et al., 2010). In addition, Aurora A activates PLK1, which
drives mitotic entry and is required for mitotic entry following G2 cell cycle arrest induced
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by DNA damage (Marumoto et al., 2002; Macůrek et al., 2008; Seki, Coppinger, Jang, et
al., 2008). Finally, inhibition of the Aurora A-PLK1 pathway under conditions of
replication stress in ATR-deficient cells allows replication forks to resume replication
(Ragland et al., 2013). Together, these data indicate that the Aurora A-PLK1 pathway
could prevent DNA damage repair through G2-M checkpoint bypass, suggesting that an
important role of the DNA replication checkpoint is to inhibit premature activation of the
Aurora A-PLK1 pathway (Figure 4.1). This is further supported by studies that
demonstrate that the Aurora A-PLK1 pathway is inhibited in response to DNA damage
as part of G2-M checkpoint activation (Medema et al., 2000; Bassermann et al., 2008;
Qin et al., 2013; Bruinsma et al., 2017).
Herein we showed that despite fork collapse being mediated through the
activation of the Aurora A-PLK1 pathway in ATR-deficient cells, it is not sufficient to
induce fork collapse in the presence of ATR. We found that overexpression of Aurora A
or stabilized mutants of Aurora A is insufficient to activate PLK1. Previous studies have
shown that co-activators bind to Aurora A and dictate its cellular location as well as its
substrate specificity. Some of these co-activators have been shown to regulate PLK1
activation and in line with these studies, we show that PLK1 activation, as determined by
its phosphorylation at the T210 site, requires co-expression of Aurora A co-activators,
TPX2 and BORA (Kufer et al., 2002b; Bayliss et al., 2003b; Eyers and Maller, 2004;
Hutterer, Berdnik, Wirtz-Peitz, Zigman, et al., 2006; Anderson et al., 2007; Seki,
Coppinger, Jang, et al., 2008; Bruinsma et al., 2013). Despite PLK1 activation,
overexpression of Aurora A in combination with TPX2 or BORA remains insufficient to
cause replication fork collapse. However, we did find that CDK1 activation is limiting in
the activation of the Aurora A-PLK1 pathway by establishing that CDK1 activation
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through WEE1 inhibition is able to hyperactivate the Aurora A-PLK1 pathway and is
sufficient to induce fork collapse into DSBs. Additionally, WEE1 inhibition prevents DNA
replication restart following replication fork stalling. These finding are expected in light of
studies that showed that WEE1 inhibition increases origin firing, leading to nucleotide
shortage followed by SLX4-MUS81 fork cleavage into DSBs (Domínguez-Kelly et al.,
2011; Beck et al., 2012) as well as studies showing that WEE1 inhibition regulate
ubiquitin-mediated

RRM2

degradation

through

premature

activation

of

CDK1

(D’Angiolella et al., 2012; Pfister et al., 2015). Notably, we found that both WEE1
inhibition-induced DSBs and inability to restart are rescued by Aurora A and PLK1
inhibition, which would suggest that nucleotide depletion is not the only mechanism by
which WEE1 inhibition leads to fork collapse. In addition, our data would indicate that
despite ATR activation, hyperactivation of the CDK1-AURKA-PLK1 pathway can
promote fork stalling and collapse into DSBs, highlighting the importance of inhibiting the
Aurora A-PLK1 pathway during DNA replication checkpoint activation to maintain
genomic stability. Finally, we establish that Aurora A overexpression leads to an
increased reliance on ATR for fork stabilization and is synergistic with ATR inhibition for
DSB formation. Many studies have shown that oncogene-induced genomic instability is
synthetic lethal with ATR inhibition (Gilad et al., 2010b; Murga et al., 2011a; Toledo,
Murga and Fernandez-Capetillo, 2011; Schoppy et al., 2012b). As we will discuss below,
clinicians have begun adopting a novel therapeutic approach based on the concept of
synthetic lethality, which ATR is proving to be an ideal candidate for. Our findings
suggest that patients with Aurora A overexpressing or amplified cancers could benefit
from ATR-targeted therapies. Interestingly, Aurora A has also been shown to be
synthetic lethal with CHK1 inhibition in ovarian cancers though we did not observe this
(Alcaraz-Sanabria et al., 2017). This inconsistency could be due to a discrepancy in
162

different types of cancers or due to the fact that full AURKA-PLK1 pathway activation is
required in order to see the synthetic lethality with CHK1 inhibition, which was likely not
achieved in our system based on our data indicating that Aurora A overexpression alone
is insufficient to lead to sufficient pathway activation that leads to fork collapse.
Together, data from the Aurora A-PLK1 pathway hyperactivation studies suggest
that ATR stabilizes replication forks and prevents their collapse into DSBs in part by
inhibiting the premature activation of the CDK1-AURKA-PLK1 pathway, highlighting the
importance of the ATR-CHK1 cell cycle progression checkpoint function for genomic
integrity (Figure 4.1). The importance of the ATR-mediated cell cycle regulation in the
DNA replication checkpoint is further demonstrated in our mechanistic dissection of
ATR-regulated fork stabilization.
ATR stabilizes stalled replication forks through its cell cycle function
The DNA replication checkpoint is integral to ensure genomic stability. Since its
discovery, many studies have contributed to expand our understanding of the players,
mechanisms and triggers involved during this response. One area of focus has been to
elucidate the mechanisms by which ATR stabilizes stalled fork and prevents them from
collapsing into DSBs (Saldivar, Cortez and Cimprich, 2017). It has been proposed that
ATR stabilizes stalled forks either through regulation of cell cycle-dependent pathways
that inhibit cell cycle progression and origin firing or through local modulation of fork
remodelers (Costanzo et al., 2003; E. J. Brown and Baltimore, 2003; Couch et al.,
2013b; Yazinski and Zou, 2016). The work presented herein provides a dissection of
ATR fork integrity functions and shows that the cell cycle function of ATR is essential in
stabilizing stalled fork in the presence or absence of replication stress (Figure 4.2). The
cell cycle checkpoint function of ATR is required both to prevent fork collapse into DSBs,
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as determined by gH2AX levels in a cell population DNA damage assay, as well as to
prevent inability of cells to reinitiate replication.
Interestingly, our data suggests that there might be two separate mechanisms by
which these functions are regulated. It appears that DSB formation is rescued by CDK1
inhibition but not by AURKA inhibition, suggesting a bifurcation of the regulatory pathway
downstream of CDK1. CDK1 is known to phosphorylate and activate nucleases in order
to resolve DNA junctions remaining after S phase to allow proper segregation of
chromosomes and to prevent chromosomal aberrations, such as breaks and anaphase
bridges (Boddy et al., 2001; Matos et al., 2011; Gallo-Fernández et al., 2012; Dehé et
al., 2013; Szakal and Branzei, 2013b; Wyatt et al., 2013a). Many structure-specific
nucleases are involved in these processes but a central player is the MUS81
endonucleases. MUS81 is the catalytic subunit of a complex that can form either with
EME1 or EME2 in mammalian cells (Ciccia, Constantinou and West, 2003; Öğrünç and
Sancar, 2003). In addition to resolving recombination intermediates and under-replicated
DNA in G2-M, MUS81-mediated nucleolytic cleavage is necessary for the restart of
stalled replication forks (Hanada et al., 2007; Alessandra Pepe and West, 2014a). The
heterodimeric complex cleaves the stalled fork into a DSB that is then repaired by
homologous recombination. Until recently, it was thought that all MUS81 functions were
mediated through the MUS81-EME1 complex but recently it was reported that MUS81EME2 is responsible for the processing of stalled replication forks to promote fork restart
(Alessandra Pepe and West, 2014a). It remains unclear how this complex is regulated,
how signaling pathway disruption could affect its function and why this function cannot
be mediated by the MUS81-EME1 complex. In S. cerevisiae, MUS81 only has one
binding partner, Mms4, which beckons the question why mammals evolved two separate
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complexes that are activated at different cell cycle stages. Although the MUS81-EME1
complex is expressed through the cell cycle, it can only resolve Holliday junctions when
bound to another endonuclease complex, SLX1-SLX4, which primarily occurs in G2-M in
a CDK-dependent manner (Castor et al., 2013; Garner et al., 2013; Wyatt et al., 2013).
Additionally, premature CDK activation of the MUS81 complex leads to aberrant
replication and increased levels of DNA crossovers (Domínguez-Kelly et al., 2011; Choi
et al., 2013; Matos, Blanco and West, 2013; Szakal and Branzei, 2013b; Duda et al.,
2016). Interestingly, both complexes exhibit a preference for 3’-flap/fork DNA structures,
yet only MUS81-EME2 can cleave a stalled fork to promote restart, whereas MUS81EME1 activation in S phase results in DSB formation and inability to restart (A. Pepe and
West, 2014). One possibility is that either these complexes process forks differently or
they recruit different proteins to promote restart. Additional studies are required to better
understand how these complexes are regulated and why they give rise to different
outcomes when activated in S phase. In the context of our studies, one model that
explains how DSB formation occurs when CDK1 is prematurely activated is that CDK1
activation aberrantly activates MUS81 resulting in stalled fork cleavage into DSBs and
that the resulting break cannot be resolved appropriately to promote fork restart (Figure
4.3). Therefore, when WEE1i-induced CDK1 activation is inhibited with CDK1 inhibition,
MUS81-EME1 is no longer active in S phase, letting MUS81-EME2 process the stalled
forks and allow for restart to occur. It remains unclear why MUS81-EME2 cannot
process and restart stalled forks when CDK1 is aberrantly activated in S phase.
Alternatively, aberrant CDK activation can hyperactivate the MUS81-EME2 complex
through a mechanism that is currently unknown and lead to inappropriate cleavage of
stalled forks. Depletion studies of EME1 and EME2 would need to be performed to
further elucidate the mechanism at play.
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Furthermore, a recent paper found that CHK1, but not ATR, depletion in the
absence of exogenous replication stress results in DNA breaks triggered by MUS81EME2 and MRE11 aberrant activation (Técher et al., 2016, 2017). In light of this study
and others, it is possible that under conditions of ATR inhibition, CHK1 is still activated
through DNA-PKcs, allowing the cell cycle checkpoint functions of ATR to be initiated.
Consequently, we observe less DNA damage in ATRi cells compared to WEE1i cells in
our system (Buisson et al., 2015). With this in mind, it would be more accurate to
compare ATRi+WEE1i to WEE1i to ensure that the cell cycle checkpoint roles of ATR
are inhibited in the ATRi sample. This comparison allows us to assess the contribution of
the local fork protection role of ATR, which appears to be minimal in our studies with 247
out of 269 WEE1i sites (92%) being affected in the ATRi+WEE1i sample compared to
only 67 out of 88 ATRi sites (76%) found in WEE1i sample. Altogether, this only serves
to further emphasize the importance of the cell cycle checkpoint functions of ATR in
replication fork stability.
We also observe that AURKA inhibition can rescue the inability of cells to restart
replication in WEE1i- and ATRi-treated cells under conditions of replication stress but it
cannot rescue DSB formation. This implies that the AURKA-PLK1 pathway prevents
replication fork restart downstream of fork cleavage (Figure 4.4). This finding is in
agreement with a study previously published in our laboratory, in which the AURKAPLK1 pathways suppresses replication reinitiation under conditions of ATR depletion
and fork stalling (Ragland et al., 2013). These findings suggest that aberrant activation
of the AURKA-PLK1 pathway could mediate restart despite the inability to prevent
endonuclease cleavage of stalled forks, as is observed under conditions of CDK1
inhibition. One mechanism independent of preventing DSB formation by which AURKA166

PLK1 inhibition rescues restart could be that of premature replisome disassembly, which
then renders the bare forks accessible to endonucleases, which would naturally process
them to promote replication restart (Figure 4.3). Additional studies are needed to
determine if replisome factors are modified and/or removed under these conditions as
well as to determine what factors might be recruited to these forks and whether or not
these changes are shared in conditions of CDK1 inhibition.
In this study, we also sought to identify sites genome-wide that might be
differentially sensitive to either of the fork stabilization functions of ATR. In agreement
with the cell population data, the RPA ChIP-Seq data showed that the majority of sites
identified depend on the cell cycle checkpoint function of ATR. Based on previous
studies that established that ATR inhibition in the absence of exogenous replication
stress did not result in DNA breaks, we expected and observed that ATRi-treated cells
led to a minimal number of hard to replicate sites (Koundrioukoff et al., 2013; Técher et
al., 2016). As expected, the number of sites increased with replication stress.
Interestingly, the number of sites seen with WEE1 inhibition alone was significantly
higher than for ATR inhibition alone. This could be a result of ATRi-treated cells still
having some part of the cell cycle checkpoint pathway active as discussed above or a
result of WEE1 inhibition inducing some inherent replication stress. Indeed, WEE1
inhibition has previously been shown to result in nucleotide depletion through RRM2
degradation, which is known to cause replication stress (Figure 4.3) (D’Angiolella et al.,
2012; Pfister et al., 2015). This finding is in agreement with a study that found that dNTP
addition suppressed fork slowing in CHK1-deficient cells but not in ATR-depleted cells,
suggesting that nucleotide depletion is an additional mechanism involved in fork stalling
under conditions of WEE1 inhibition (Técher et al., 2016). Interestingly, though WEE1
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inhibition increased the number of sites sensitive to fork collapse, it did not affect their
intensity. One might expect that increased replication stress could result in an
amplification in the breakage frequency of these sites as opposed to or in addition to an
increase in the number of sites that are affected genome-wide. It would be interesting to
see if lower doses of inhibitor could reveal a replication stress-induced increase in the
frequency of sites undergoing fork collapse. If not, this could imply that there might be a
cap in the frequency that certain sites in the genome can collapse before cell deathinducing mechanisms are activated or that specific sites in the genome have a
predetermined replication stress threshold at which they collapse, resulting in increasing
fork collapse sites as replication stress increases. Additional studies would need to be
performed to determine if this occurs. As previously discussed, because ATR inhibition
alone could still allow cell cycle functions of ATR to be activated through redundant
upstream kinases, such as ATM and DNA-PK, it would be more appropriate to compare
WEE1i to ATRi+WEE1i with or without aphidicolin. Indeed, when comparing these
conditions, they lead to a similar number of total sites as well as a significant overlap
between each other.
Another unexpected finding was that genomic loci sensitive to WEE1i and
ATRi+Aph only overlapped by 54%. Based on the cell population DNA damage and
restart assays, we anticipated them to almost completely overlap. This suggests that the
replication stress induced by aphidicolin and WEE1 inhibition are distinct and result in
different fork stalling patterns. By determining which features characterize these unique
sites will provide us with insight into the mechanisms by which these two stressors result
in replication perturbation. An interesting hypothesis to test would be to investigate
whether the site unique to WEE1i treatment are enriched in adenines and guanines as
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nucleotide depletion resulting from RRM2 degradation, based on HU data, would
preferentially deplete dATPs and dGTPs (Collins, Oates, & Collins, 1987 and personal
communications with Dr. D'Angiolella).
Together these data indicate an essential role for the cell cycle checkpoint
function of ATR in stabilizing replication forks though the local role of ATR might also
play stabilizing functions at a few sites in the genome (Figure 4.2). Future studies are
required to determine what features render these sites vulnerable to fork stalling and
collapse as well as what mechanisms lead to fork collapse.
Therapeutic implications and combinatorial treatments
As previously mentioned, ATR inhibition is actively being pursued in clinics to be
used in combinatorial treatments with DNA damaging agents as well as with other
proteins that synergize with ATR inhibition (Weber and Ryan, 2015; Blackford and
Jackson, 2017; Sundar et al., 2017). Originally, ATR inhibitors were not actively pursued
as therapeutics because ATR knockout mice were embryonic lethal (Brown and
Baltimore, 2000; de Klein et al., 2000). It was then discovered that hypomorphic
mutations were viable through the studies of Seckel syndrome (O’Driscoll et al., 2003).
Though ATR proved to be essential for cell viability and genomic stability, hypomorphic
levels of ATR were not toxic for cells in the absence of replication stress. However,
under conditions of replication stress, such as that induced by oncogenes, ATR loss
proved to be lethal (Murga et al., 2009, 2011a; Gilad et al., 2010b; Toledo, Murga and
Fernandez-Capetillo, 2011; Schoppy et al., 2012b). These studies paved the way for
applying the concept of synthetic lethality for the selective targeting of tumors
(McLornan, List and Mufti, 2014; O’Neil, Bailey and Hieter, 2017). By targeting tumors
with a mutational landscape that induces a reliance on the ATR-regulated cell cycle
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checkpoint, ATR inhibitors specifically prevent tumor growth and viability without
affecting surrounding healthy cells. ATR loss has been shown to be synthetic lethal with
DNA damaging chemotherapeutic agents, p53, XRCC1, ERCC1, ATM, MYC, RAS and
many other proteins (Reaper et al., 2011; Sultana et al., 2013; Mohni et al., 2015; Hocke
et al., 2016; Kwok et al., 2016; Sanjiv et al., 2016; Williamson et al., 2016). Studying the
mechanisms by which ATR prevents genomic instability allows for the identification of
new synthetic lethal interactors, such as proteins in the Aurora A-PLK1 pathway.
AURKA is frequently amplified in a spectrum of cancers, including ovarian,
colorectal, and breast cancers and its overexpression correlates with poor prognosis and
increased genomic instability. AURKA overexpression was recently shown to predict
poor overall survival and early recurrence of triple negative breast cancer patients. By
elucidating the mechanisms by which AURKA contributes to replication fork collapse and
how its hyperactivation leads to an increased reliance on ATR, we can develop targeted
therapies for AURKA-amplified cancers and use AURKA-PLK1 pathway hyperactivation
as a prognostic indicator for ATR inhibitors, which are currently in clinical trials for
several cancers. In addition, oncogene expression has been shown to increase
dependency on ATR for genomic stability and cancer cell survival, thus promoting a
synthetic lethal effect when treated with ATR inhibitors. Some of these oncogenes, such
as KRASG12D and MYC, are known to promote AURKA expression and activity. Our
finding showing that AURKA overexpression sensitizes cells to ATR inhibition suggests
that AURKA-PLK1 pathway hyperactivation is one mechanism by which these
oncogenes are synthetic lethal with ATR inhibition. Moreover, these findings indicate that
AURKA amplification or overexpression could serve as a biomarker for ATR-based
therapies.
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Finally, it has been reported that chemically-induced and oncogene-induced
replication stress give rise to different landscapes of fragile sites that only partially
overlap with one another (Miron et al., 2015). The underlying features that render some
sites over others more prone to genomic instability under differing conditions remains
unknown. Our studies contribute to our knowledge of which sites are more vulnerable to
cell cycle checkpoint abrogation and could bring insight into how specific sites might
result in lethal genomic instability. Determining genomic regions that are more sensitive
to ATR or WEE1 inhibitors, both of which are currently in clinical trials for various
cancers, will also allow us to determine if these loci contribute to the synthetic lethality
observed with AURKA inhibition or oncogene expression. It is possible that a
combination of specific sites achieved by combinatorial inhibition results in lethality.
Alternatively, lethality could be due to an increase in the frequency of breakage at
specific sites, which might give rise to fatal chromosomal translocations. Further
characterization of these sites would allow us to determine if features specific to these
sites, whether it be sequence, gene expression, chromatin modifications, etc., are key to
tumor cell death while others have little effect. Together, these data could be used to
develop more targeted cancer therapeutics that minimize off-target effects on healthy
cells as well as be used as predictive biomarkers to maximize the efficacy of therapies in
specific patient subpopulations.
Future Directions
The projects described herein leave many interesting avenues to pursue. For
future directions regarding the AURKA-PLK1 pathway activation studies, it would be of
interest to further test if cancer cells that have AURKA amplification or Aurora A
overexpression are synthetic lethal with WEE1 inhibition. If this were the case, these
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findings would support using WEE1i inhibitors to treat Aurora A overexpressing tumors
in patients.
One interesting avenue to pursue based on the findings in Chapter 3 is to
determine which features characterize RPA ChIP sites unique to each condition tested
and to determine if sites unique to WEE1i compared to ATRi+Aph were enriched in
adenines and guanines. If so, we would expect that supplementing dATPs and dGTPs to
the WEE1i treatment media would prevent these sites from accumulating RPA. To gain
an understanding of the mechanism by which these sites collapse, it would also be of
interest to establish which sites can be rescued by AURKA or CDK1 inhibition as well as
what might be the difference between these sites. Finally, determining which nucleases
might be involved in fork cleavage into DSBs would be informative to understand
whether cleaved forks are the results of premature activation of G2-M nucleases or
whether fork cleavage is the result of aberrant activation of S phase-specific nucleases,
such as MUS81-EME2 (Fekairi et al., 2009; Muñoz-Galván et al., 2012; Ragland et al.,
2013; Wyatt et al., 2013b, 2017; Alessandra Pepe and West, 2014a).
Genome wide analysis of BrITL-Seq data
Though much of the RPA ChIP-Seq data still needs to be mined, this dataset
lacks the ability to distinguish between stalled replication forks that have accumulated
ssDNA and RPA-coated resected DSBs (Figure 4.5). Our laboratory has developed an
assay, Breaks Identified by TdT-Labeling (BrITL), to isolate genomic loci at which DSBs
occur genome-wide. The BrITL assay was performed on the same conditions as the
RPA ChIP experiment with the addition to sample in the absence and presence of
CDK1i to determine if fork cleavage into DSBs is CDK1-dependent. Genome wide
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sequencing data analysis remains to be performed on these samples but characterizing
the sites that overlap between RPA-Seq and BrITL-Seq would be interesting to
determine if all of them are CDK1-dependent, and whether some conditions are more
prone to having sites collapse into DSBs as opposed to being collapsed fork unable to
restart replication.
Proteomic analysis of iPOND2 data
WEE1 inhibition leads to ATR-CHK1 activation within 15 min and to DSB
formation by 1 hr. Studies have previously reported that WEE1 inhibition leads to an
increase in MUS81-EME1 at the fork and results in fork cleavage and DSB formation
(Beck et al., 2010, 2012; Domínguez-Kelly et al., 2011). In addition, WEE1 inhibition
activates the AURKA-PLK1 pathway, which was shown to promote replication fork
collapse following ATR inhibition (Ragland et al., 2013). Finally, studies have shown that
PLK1 can mediate degradation of Claspin and FANCM, two replisome components
(Mamely et al., 2006; Kee et al., 2009). Based on these findings, we speculate that
WEE1 inhibition induces many dynamic changes at the replication fork, possibly
including premature removal of replisome components leading to bare fork structures
that are cleaved by nucleases (Figure 4.3). Using isolation of Proteins On Nascent DNA
(iPOND), we monitored protein changes that occurred after 30 min or 2 hrs of WEE1
inhibition by Western immunoblotting. We observed an increase in phosphorylation of
ATR substrates at 30min of WEE1 inhibition and a decrease in protein ubiquitination at
the fork at 2 hrs, suggesting that WEE1 inhibition causes replication stress that activates
the ATR-CHK1 response rapidly and that following DSB formation, many previously
ubiquitinated replisome components are removed or deubiquitinated (Figure 4.6).
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To better understand how WEE1 inhibition affects replisome dynamics, we
performed iPOND2-mass spectrometry (MS) on WEE1i, WEE1i+Aph, WEE1i+ATRi,
WEE1i+CDK1i, WEE1i+Aph+CDK1i, WEE1i+ATRi+CDK1i, ATRi and ATRi+Aph for 2
hrs and WEE1i and WEE1i+Aph for 30 min. These samples will provide insight into how
WEE1 inhibition alters protein recruitment or loss at the fork as well as their state of
ubiquitination, how WEE1 inhibition synergizes with ATR inhibition and if it is CDK1dependent. The analysis will entail monitoring changes in protein abundance and
ubiquitination status at the replisome in the different conditions. Preliminary analysis
suggests that WEE1 inhibition decreases ubiquitination-mediated degradation and
upregulates metabolic pathways as well as repair pathway as expected from our
preliminary findings. More specifically, WEE1i resulted in a downregulation of
proteasome, aminoacyl-tRNA biosynthesis, spliceosome and FA pathway proteins and
an upregulation of metabolic pathways, ribosome and carbon metabolism pathway
proteins. WEE1i+Aph treatment lead to a downregulation of spliceosome, ubiquitin
mediated proteolysis, cell cycle and RNA transport pathway proteins and an
upregulation of metabolic pathways, aminoacyl-tRNA biosynthesis, spliceosome, FA and
HR pathway proteins. WEE1i+ATRi+Aph resulted in a downregulation of carbon
metabolism, metabolic pathways, and an upregulation in spliceosome, DNA replication,
cell cycle, ribosome and nucleotide excision repair pathway proteins. ATRi leads to
downregulation of carbon metabolism, mismatch repair, metabolic pathways, and DNA
replication and to an upregulation in spliceosome, ribosome, RNA transport pathway
proteins. ATRi+Aph results in downregulation of spliceosome, proteasome, carbon
metabolism, and to an upregulation of ribosome, HR, RNA transport, FA and DNA
replication pathway proteins. CDK1i in WEE1i treated cells compared to WEE1i treated
cells leads to the downregulation of ribosome, carbon metabolism, metabolic pathways
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and TCA cycle pathway protein and upregulates spliceosome, RNA transport,
proteasome and ubiquitin mediated proteolysis as well as aminoacyl-tRNA biosynthesis.
Detailed analysis of this wealth of data needs to be performed as does analysis of the
data on the ubiquitination state of replisome components observed at the fork under
these conditions. As expected, WEE1 inhibition activates and recruits repair pathway
proteins at the forks as these are likely to stall and need repair under conditions of
WEE1 inhibition. Additionally, WEE1i treatment appears to downregulate proteasomemediated degradation pathway proteins, which could explain why we observed a
reduction in levels of ubiquitination at the fork under WEE1 inhibition by Western
immunoblotting.
Studies performed in human cells
All findings presented in Chapter 3 were performed in mouse cells; however,
performing similar studies in human cell lines would provide therapeutically relevant
information. Human breast cancer cells from the MDA-MB-231 cell line were treated with
WEE1i and ATRi in the presence and absence of aphidicolin and BrITL-Seq was
performed. Though the analysis is preliminary, new sites were identified and appeared
enriched in A/T-rich repeats. It would be interesting to see if these sites could be
rescued through supplementation of dATPs and dTTPs to determine if these sites occur
from a lack of nucleotides or whether these sequences have intrinsic characteristics that
render them inherently prone to breakage, such as being structure forming. Again,
comparing sites unique to each condition and determining their features as well as
establishing common features that promote DSB formation would be really interesting.
These features might be able to explain why the human genome has cancer
translocation hotspots or these features could be used to artificially create break spots in
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the genome by inserting them at a site of interest. Finally, if each treatment results in a
unique breakage signature, these could be combined with breakage signatures unique
to cancers, such as ones created from oncogenes, to specifically target cancer cells
through synthetic lethality.
Figure Legends
Figure 4.1. Model figure: ATR stabilizes forks by preventing the premature activation of
the CDK1-AURKA-PLK1 pathway. When ATR is absent or inhibited, the AURKA-PLK1
pathway is prematurely activated and results in premature entry into mitosis as well as in
the degradation or removal of replisome components, leading to fork stalling and inability
to restart replication.
Figure 4.2. Model figure the fork stabilizing functions of ATR. ATR stabilizes forks
through its direct fork protection role (phosphorylation of substrates directly found at the
replication fork) and through its cell cycle checkpoint role (signaling cascade triggered
through activation of downstream effectors, not permanently localized at the fork, such
as CHK1 and WEE1).
Figure 4.3. Signaling cascades activated by WEE1 inhibition that result in fork stalling.
WEE1 inhibition has been shown to activate CDK1-AURKA-PLK1 pathway, which leads
to fork stalling, to activate CDK2, which leads to aberrant origin firing and to lead to
RRM2 degradation and endonuclease activation. All of these signaling pathways have
been shown to lead to replication fork stalling.
Figure 4.4. Signaling cascades downstream of CDK1 that result in fork stalling and
collapse. WEE1 inhibition activates CDK1 which in turn activates the AURKA-PLK1
pathway that is known to lead to fork stalling. CDK1 activation also leads to RRM2
degradation that is known to lead to fork stalling through nucleotide depletion. CDK1
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activation is also known to activate endonucleases such as MUS81-EME1 that have
been shown to cleave forks. This figure summarizes the different pathways downstream
of CDK1 that could contribute to fork stalling and eventual fork collapse.
Figure 4.5. Structures enriched in RPA ChIP assay compared to BrITL assay. The RPA
ChIP assay isolates genomic loci that are enriched in RPA. As such, it enriches for and
cannot distinguish between collapsed forks that are either unable to restart replication or
that have collapsed into DSBs. The BrITL assay enriches for forks that have collapsed
into DSBs. By comparing the peaks obtained with both assays, the sites at which DSBs
occur as opposed to sites at which forks cannot restart replication can be determined.
Figure 4.6. WEE1 inhibition results in decreased protein ubiquitination and increased
ATR substrates phosphorylation at the fork. (A) Representative Western blot of input or
captured proteins following iPOND on 4-3 MEF cells treated with 3 µM WEE1i for 30 min
or 2 hr and then labeled for 10 min with EdU. Levels of ATR substrate activation, such
as phosho-MCM2, phospho-CHK1, phospho-RPA32, as well as levels of total MCM2
and total RPA70 were assessed. (B) Representative Western blot of input or captured
proteins following iPOND on 4-3 MEF cells treated with 3 µM WEE1i for 30 min or 2 hr
and then labeled for 10 min with EdU. Levels of protein ubiquitination was assessed.
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